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Professor Sharan Ramaswamy, Major Professor
Articular cartilage injuries occur frequently in the knee joint. Several methods have
been implemented clinically, to treat osteochondral defects but none have been able to
produce a long term, durable solution. Photopolymerizable cartilage tissue engineering
approaches appear promising; however, fundamentally, forming a stable interface between
the tissue engineered cartilage and native tissue, mainly subchondral bone and native
cartilage, remains a major challenge. The overall objective of this research is to find a
solution for the current problem of dislodgment of tissue engineered cartilage at the defect
site for the treatment of degraded cartilage that has been caused due to knee injuries or
because of mild to moderate level of osteoarthritis. For this, an in-vitro model was created
to analyze the integration of tissue engineered cartilage with the bone, healthy and diseased
cartilage over time. We investigated the utility of hydroxyapatite (HA) nanoparticles to
promote controlled bone-growth across the bone-cartilage interface in an in vitro
engineered tissue model system using bone marrow derived stem cells. We also
investigated the application of HA nanoparticles to promote enhance integration between
tissue engineered cartilage and native cartilage both in healthy and diseased states. Samples
incorporated with HA demonstrated significantly higher interfacial shear strength (at the
junction between engineered cartilage and engineered bone and also with diseased
cartilage) compared to the constructs without HA (p < 0.05), after 28 days of culture. These
findings indicate that the incorporation of HA nanoparticles permits more stable anchorage
of the injectable hydrogel-based engineered cartilage construct via augmented integration
between bone and cartilage.
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Chapter 1
Introduction
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1.1 Introduction
The aim of the study was to develop a photo polymerizable injectable tissue
engineered cartilage model. This model possesses enhanced integration properties for the
treatment of focal cartilage injuries and mild to moderate level of osteoarthritis (≤50mm2).
Our central hypothesis was that an osteoinductive approach will overcome the existing
limitations of securing engineered cartilage within the defect space for the complete
healing period. To test this hypothesis, we conducted an in-depth analysis of the integration
of the newly formed tissue engineered cartilage to bone as well as to diseased and healthy
cartilage tissues.
1.2 Background
Articular cartilage defects and lesions are one of the most common injuries that
occur in the knee joint [1, 2]. Curl et al [1], demonstrated in their study of consecutive knee
arthroscopies that up to 63% of the patients with knee-related symptoms suffered from
chondral or osteochondral defects [3]. These defects may also progress to osteoarthritis if
left untreated [4], which further involves degradation of articular cartilage, the sub chondral
bone, the synovial capsule and membrane as well as the periarticular tissues [5].
Cartilage provides a cushioning mechanism to minimize the impact to bone at joint
locations, by completely covering its free surface. Conversely, the degradation of articular
cartilage leads to the exposure of bone and eventually, bone-to-bone contact which can
cause considerable pain and stiffness in the joints. The extra cellular matrix of articular
cartilage is composed of collagen–II and proteoglycans which are maintained and
synthesized by chondrocyte cells. The tissue does not contain any vasculature hence,
attributing to the slow rate of growth and repair [6, 7]. Architecturally, cartilage is
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composed of 3 zones (Fig. 1.1) and can be classified according to the orientation of
collagen fibers within the tissue [8, 9]. The superficial layer has a tangential orientation
with respect to the free surface, while the middle transitional layer is more random. Finally,
the deep zone is orientated orthogonally to the free surface.
Several methods have been implemented clinically to treat osteochondral defects
but none have been able to produce a long term, durable solution [10-12]. Current
clinically used strategies involve permanent modification of the damaged articular surface
using abrasion arthoplastry or shaving of chondral bone to remove any loosen bits or parts
to ease out the pain. Another popular technique in severe cases of OA makes use of grafting
procedures, such as mosaicplasty [13, 14] or osteochondral allograft transplantation. In
situations of complete cartilage loss and/or severe pain, total joint replacement is carried
out, such that an implant consisting of artificial materials is implanted. While these
implants have demonstrated durability > 10 years, revisions are required and the procedure
is expensive [15]. From a regenerative medicine standpoint, autologous chondrocyte
transplantation (ACT) has been used to promote [16, 17] chondrogenesis. In addition, of
keen interest in cartilage tissue engineering, several approaches involve leveraging bone
marrow derived stem cell (BMSC) release from the subchondral bone, which involve
drilling [18] or microfracture [19] of the same with the hope that BMSCs will migrate in
the defect area and promote cartilage repair. While these tissue engineering approaches
seem promising, fundamentally, there is still a need to better integrate the biomaterial to
the host to allow for sufficient repair and regeneration of new cartilage tissue.
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Figure 1.1: Zonal structure of articular cartilage. The superficial zone contains collagen fibers
aligned tangentially to the joint surface, whereas the intermediate zone has a more random
orientation. Finally, the deep zone of cartilage is characterized by a perpendicular arrangement of
collagen fibers

Successful integration will require overcoming the following two major challenges:
1) the biomaterial scaffold that is used must initially be harmonized in the joint, and the
ensuing developing tissue must amalgamate with the existing native tissue that surrounds
it; 2) the mechanically hostile environment of the joint poses further challenges and thus
must be overcome by tailoring suitable interfacial mechanical properties after integration
of the biomaterial to subchondral bone, so that de novo cartilage tissue can adequately
form.
1.3 Objectives of the current research
The overall objective of this research (Fig. 1.2) is to find a solution for the current
problem of dislodgment of tissue engineered cartilage at the defect site for the treatment of
degraded cartilage that has been caused due to knee injuries or because of mild to moderate
level of osteoarthritis. For this, an in-vitro model is created to analyze the integration of
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tissue engineered cartilage with the bone, healthy and diseased cartilage over time. This
overall objective is achieved through the following specific aims:
Aim 1: Promote integration between engineered cartilage to subchondral bone using
hydroxyapatite nanoparticles in an optimized photopolymerizable hydrogel environments,
which will permit controlled bone in-growth into a modest region (5-15%) of the
engineered cartilage space, thereby providing enhanced anchorage.
Aim 2: Enhance the integration between tissue engineered cartilage and surrounding native
cartilage, again with hydroxyapatite nanoparticle incorporation in photopolymerizable
hydrogel environments.
Aim 3: Demonstrate the sustenance of engineered cartilage in presence of osteoarthritic
diseased states, using approaches utilized in aim 2 and to show their integration in diseased
state under hydroxyapatite nanoparticles environments.
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Figure 1.2: Overall Strategy of the Research

As observed by the reader, this chapter gives the background information and motivation
for the ongoing project. The subsequent organization of this dissertation is as follows:
Chapter 2 provides a comprehensive literature review of investigations that has been done
by other researchers in the field of integrating and fixing the tissue engineering cartilage.
It also provides the ideas of research areas that can be further exploited. Chapter 3 presents
a study of the cellular cytotoxicity of five different human cell sources at different UV
exposure times, with and without a commercially used photoinitiator. This chapter provides
insights on the relative survivability of the different cells under UV light and photo initiator
environments and forms a foundation for subsequent usage of some of these cell types
(bone marrow stem cells and osteoblasts) for our tissue engineering experiments. Chapter
4 describes the study for the investigation of the utility of hydroxyapatite (HA)
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nanoparticles to promote controlled bone-growth across the bone-cartilage interface in an
in vitro engineered tissue model system, using bone marrow derived stem cells. Chapter 5
describes the integration of tissue engineering cartilage with healthy and diseased cartilage
tissues when HA nanoparticles are utilized. Conclusions and scope of future research for
this study will be discussed in Chapter 6. Recommendations will also be provided so that
this research can enter into the next stage for in vitro model.
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Literature Review
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This chapter presents a critical review of investigations that have been conducted in
integrating engineered cartilage to host tissue. The process of integration of tissue
engineered constructs can be broadly classified into three main categories.
a) Mechanical fixation
b) Chemical Fixation
c) Biological fixation
2.1 Mechanical fixation
2.1.1 Sutures
Sutures have been extensively used to stabilize implants [1]. An ideal suture has
characteristics of high tensile strength, excellent knot security, minimal tissue
inflammation, and biocompatibility [2, 0]. Sutures are made of a variety of textile materials,
including, Dexon, silk, nylon, polyethylene and Chitin [0, 5]. However sutures alone are
not able to enable total fixation. Robertson et al [6], reported that the suturing process
normally leads to the tearing of tissue when load is applied. Moreover premature suture
breakage frequently occurs during application of a load. In some cases the suture threads
actually pulled the implant away from the defect site resulting in dislodgement [6].
2.1.2 Screws
Screws have been utilized to anchor tissue engineered constructs to bone [7]. They act as
a stabilizing device that helps to retain the construct in the defect. The main disadvantage
of screws is that they possess protruding components which create regions of stress
shielding and can alter bone material properties. In addition the protrusion may interfere
with the seamless movement of joints at the articulating surfaces.
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2.1.3 Cross Pins
To overcome the limitations of screws, cross pins were utilized so as to augment stability
to the implant. Cross pins are much thinner than screws, thus enabling them to fix the tissue
engineered constructs to the bone without eliciting substantial tearing [8]. In this technique,
many research groups [8, 9] used a pin fixture which degrades over time. Pins offer many
advantages over screws, in that they prevent graft laceration and their heads are softer than
screws, which reduces damage to the engineered constructs.
2.1.4 Staples
Robertson et al [6], reported that use of staples is the most effective method of mechanical
fixation of tissue engineered constructs to bone. However the most common mode of
failure for staples was their dislodgment after application of load. In addition, Shall et al
[10], reported that staple breakage and pull-out were the two main reasons for fixation
inadequacies.
Mechanical fixation manifests itself through a direct physical connection between implant
and the bone. However the primary limitation in these approaches are that they form a
sharp interface rather than a natural, graded integration between engineered to native tissue
structures, which ultimately leads to implant loosening over a period of time. Considerable
efforts have gone into determining novel ways of mechanically fixing implants to host
tissue. Nonetheless, true integration of engineered to native tissues such as bone cannot be
achieved without biological growth and assimilation across the interface. In addition,
mechanical fixation alone may cause secondary tissue damage owing to new defect
creation during processes such as suturing and stapling, which cannot be easily repaired
[11].
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2.2 Chemical Fixation
There are a number of chemical-based methods that have been attempted to fix tissue
engineered constructs to bone in animal models such as tissue adhesives [0, 13], treating
the construct with enzymes[25, 26] and blocking signaling pathways [29]. These methods
have shown some success in terms improving the mechanical stability and durability of the
implant. Some of the approaches which have used a chemical approach are described
below:
2.2.1 Tissue Adhesives
Tissue adhesives have been used for minor wound repair [0]. They have been implemented
in place of sutures and staplers for enabling improved outcomes for wound closure [13].
There are a variety of tissue adhesives that have been used clinically. The primary
adhesives are described as follows:
Cyanoacrylates are a class of tissue adhesives that have been extensively used. There are
many derivatives of cyanoacrylates such as N-butyl cyanoacrylate, 2-Octylcyanoacrylate,
butyl-2-cyanoacrylate and N-butyl-2-cyanoacrylate [14, 15, 16]. These cyanoacrylates are
commonly referred to as “superglues”. They are liquid monomers which cause an
exothermic reaction and form a flexible film at the tissue surface that will subsequently
hold the two parts together [17]. Vote et al [18], reported that cyanoacrylate prevents the
re-occurrence of epithelialization within the damaged area and the connective tissue.
Cyanoacrylates also minimize infection because of their bacteriostatic properties which
serve to inhibit the growth of gram positive organisms [15, 18].
Bioglue is another type of tissue adhesive that consists of albumin gluteraldehyde. It is
composed of purified bovine serum albumin cross linked with gutaraldehyde. Herget et al

13

[0], suggested that this glue was suitable for sealing lung parenchyma and bronchial
anastomosis defects. They furthermore reported that bioglue is durable and its adhesive
capability is effective [0]. Several surgical procedures utilize fibrin glue. This tissue
adhesive is composed of fibrinogen and thrombin linked together with a bond formed via
the coagulation reaction [20]. Fibrin glue also consists of antifibrinolytic agents, aprotinin
and calcium chloride in addition to the primary fibrinogen and thrombin components [21].
It has been successfully and actively used as a sealant for pulmonary air leaks [22]. In
addition, although fibrin glue is found to be chemically less toxic then cyanoacrylates, they
possess less adhesive strength properties [23], thus limiting their use in tissue integration
processes.
2.2.2 Enzymatic Approaches
Enzymatic treatment approaches work on the principle that selective enzymatic treatment
of tissue engineered constructs will promote integration to the host tissue and thereby
provide better fixation.

Many enzymatic treatments have been attempted and have

demonstrated improved integration outcomes. For example, Hunziker et al [25], suggested
that the removal of proteoglycans from the surface would enhance the repair of cartilage.
Their hypothesis was based on the fact that the cells that are responsible for repairing and
regenerating the tissue in cartilage injury do not adhere to proteoglycan rich surfaces. Thus
the removal of these proteoglycan molecules from the surface of defects by the use of the
enzyme, chondroitinase ABC would enhance the cartilage repair process. From their
experiments, they were able to show that the repair cells adhered to the defect surface
considerably better on removal of proteoglycan molecules; however, they were not able to
show that the chondroitinase treatment actually enhanced the healing of the injured tissue.

14

Lee et al [26], reported that chondroitinase treatment at various concentrations of the
enzyme and exposure durations altered adhesion behavior of transplanted cells for the
repair of the injured tissue. However, low concentrations of the enzyme (0.25 U/mL) for
15 minutes (and alternatively, 0.5 U/mL for 5 minutes) had no effect in improving adhesion
of the cells. Bravenboer et al [27], suggested that integration of engineered cartilage
constructs can be enhanced by enzymatic treatment of collagenase and hyaluronidase. They
furthermore reported that treatment of these enzymes on the implanted tissue construct will
increase the mechanical properties at the interface of engineered to host tissues. The same
group had also previously showed that treatment with collagenase and hyaluronidase
increased the cell density to the wound site [28]. Although there was significant increase
in the integration strength of the implanted tissue model to native tissue using this dual
enzymatic treatment, the reported values were ~ seven times lower than the actual strength
of intact cartilage to subchondral bone [27]. Nonetheless, enzymatic treatments may offer
a very promising addition when used in conjunction with potential tissue integration
strategies that utilize biological fixation methodologies.
2.2.3 Signaling Pathway /Biochemical Approaches
A blocking signaling pathway responsible for degrading tissue may indirectly promote the
integration of the tissue engineered construct to native tissue. Recently Djouad et al [29],
conducted experiments involving the blocking of the signaling pathway of extracellular
regulated kinases (ERK). They found that disintegration of the extracellular matrix in
native cartilage is aggravated by the degradative signaling cascades which were initiated
by proinflammatory cytokines. Thus blockage of extracellular regulated kinases 1 and 2
were thought to improve the integration processes between engineered to host cartilage.
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Elsewhere [30, 31], it was reported that interleukin 1-β(IL1- β) and tumor necrosis factorα(TNF-α) are two important factors that are mainly responsible for causing the
extracellular matrix (ECM) degradation and that they stimulate the formation of ERK 1/2,
a protein molecule which is responsible for cartilage degradation. Djouad et al [29], were
successful in blocking IL1- β and TNF-α signaling and subsequently were able to measure
improved biochemical and mechanical properties at the interface of engineered cartilage
and native tissue. However the de novo cartilage tissue as a whole had lower mechanical
properties; for example, their control samples had a Young’s modulus of 17.7- 5.5 kPa
while their samples treated with IL1-b– and TNF- recorded values of 7.30-2.8 kPa and
11.5-1.7 kPa, respectively.

These results suggests that integration processes using

signaling pathway alteration approaches may improve at the cost of deteriorated engineered
tissue bulk mechanical properties. Overall, a variety of chemical-based approaches have
been used, but none of them have been capable of achieving durable integration with native
tissues. Thus the demand for strong and durable integration of the engineered implant to
native tissues [24] may only be possible with biological fixation measures.
2.3 Biological Fixation
Biological fixation approaches serve to enhance integration of tissues by true biological ingrowth and amalgamation. Some of the techniques that are used have been categorized
below.

2.3.1 Chondroitin Sulphate

16

The incapability of tissue adhesives to provide a stable and durable fixation over a period
of time without causing any infection and maintaining the biocompatibility, particularly in
the area of cartilage tissue engineering, led to integration studies involving multifunctional
chondroitin sulphate [24]. Wang et al [24], reported that this material was chemically
functionalized by two groups, methacrylate and aldehyde which can form a covalent bond
to adhere to native cartilage on one side and the biomaterial scaffold on other side, thus
forming a strong primer between the host and engineered tissues [24]. They also suggested
that the material was bioactive as chondroitin sulphate is a principal component of cartilage
ECM which would thereby serve to augment tissue repair.
2.3.2 Chitosan
Chitosan is a polysaccharide which is biocompatible, biodegradable, non-toxic and
allergen free. Chitosan has a hydrophilic surface which promotes both cell adhesion and
proliferation [32]. Hoemann et al [33], indicated that Chitosan glycerol phosphate when
mixed with blood in the cartilage defect space not only greatly improved integration with
sub-chondral bone, but also resulted in enhanced hyaline cartilage tissue formation.
However, chitosan has low strength [34], so it cannot be used alone in the fixation process.
2.3.3 Hydroxyapatite
Hydroxyapatite (HA) (or calcium phosphate) is a bioactive material found in the bone and
teeth. A few research groups have been working on providing enhanced engineered
cartilage to bone anchorage through the use of this bio active material [35, 52]. One of the
research group Lu et al [51], evaluated the potential of HA in alginate gel for regeneration
of osteochondral interface and they were able to demonstrate successfully the formation of
calcified cartilage like with the use of HA in their system.
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A summary of the different integration methods for engineered cartilage tissue constructs
to bone, which were presented in this chapter, is described in Table 2.1:
Table 2.1: Summary of the advantages and disadvantages of different types of integration
techniques [1-36]
Fixation

Specific

type

approaches

Mechanical
Fixation

Sutures

Advantages

Disadvantages

- Extensively used for
retaining construct with the
bone

- Premature suture
Breakage

-

Inexpensive

- Tearing of Tissue
engineered constructs

Screws

- Help in retaining the
constructs with the bone

- Protruding heads
leads to the tearing of
tissue and affects the
bone shear

Cross Pin

- Thinner than screws and soft
heads

- Breakage

- prevents graft laceration
Staples

Chemical
Fixation

Tissue Adhesives

- Most effective method for
mechanical fixation

- Durable

- Dislodgement of
staples after the
application of load.
-

Staple breakage

-

Staple pull out

- Some are not biocompatible
- They prevent the
epithelialization within
the damaged area and
connective tissue
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- They may cause
infection
Enzymatic

- promote integration between
the implant and the native
tissue

- Alone this treatment
cannot provide enough
strength

- indirectly promote the
integration of the tissue
engineered constructs with
native tissue

- They deteriorate
engineered tissue bulk
mechanical properties

Chondroitin
Sulphate

- Bioactive material

Was not able to form a
strong force of
interaction between the
host and the tissue
engineered constructs

Chitosan

- Biocompatible

- Low Strength

treatment
Biochemical
Approach

Biological
Fixation

- Biodegradable
- Allergy free
- Non toxic
Hydroxyapatite

-Bioactive material
- Help in the formation of deep
layer of cartilage from bone
marrow derived stem cells

- Ceramic, may break
at a sudden load

In summary, current paradigms in cartilage tissue engineering do not sufficiently address
the issue of integrating engineered construct to native host tissue. The different approaches
relating to this critical area, which are mechanically, chemically or biologically driven,
have been discussed in this chapter and these techniques alone have not been able to
provide a durable integration with the host tissue and fixation in the defect area.
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Hence, the primary objective of the proposed research was to focus on the use of injectable
polymers as a model system to assess integration processes and efficacy, leveraging a
biological-fixation-based strategy. In line with other investigators [37, 38], my motivation
for such an approach is that injectable approaches have the ability to introduce a monomer
solution to fill arbitrarily-shaped defects while concomitantly incorporating any secondary
substance; Polymerization (e.g. via UV exposure and photoinitiator inclusion) can then
occur in situ [39].
For biological fixation we chose to experiment with hydroxyapatite nanoparticles in a
photopolymerizable hydrogel system owing to its well-established

osteoinductive

properties The effects of hydroxyapatite incorporation were then assessed not only in the
context of integration to bone, but also with healthy and disease cartilage tissues.
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Chapter 3
Relative survivability of different human cell types after exposure to
photopolymerizable environments

This chapter presents a study of the cellular cytotoxicity of five different human cell
sources at different UV exposure times, with and without a commercially used
photoinitiator. The work presented herein formed the foundation for subsequent protocols
that were designed in conjunction with in vitro engineered tissue model systems for
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evaluating integration of engineered bone to engineered cartilage. This topic is presented
in detail in chapter 4 of this dissertation. In particular, osteoblasts which are very sensitive
to photopolymerizable environments were able to remain viable for longer durations under
specific incubation temperature and biochemical conditions as described below.
3.1 Abstract
Photopolymerizable hydrogels offer great potential in cartilage tissue engineering due to
their ability to conform to irregular defect shapes and be applied in a potentially minimally
invasive manner. An important process requirement in the use of photopolymerizable
hydrogels is the ability of the suspended cells to withstand low intensity ultraviolet light
(UV) exposure (4–5 mW/cm2) and photoinitiator concentrations. For cartilage integration
with underlying subchondral bone tissue, robust localized osteoblast activity is necessary.
Yet, while it is known that osteoblasts do not respond well to UV light, limited work has
been conducted to improve their survivability. In this study, we evaluated the cellular
cytotoxicity of five different human cell sources at different UV exposure times, with and
without a commercially used photoinitiator. We were able to confirm that human
osteoblasts were the least tolerant to varying
UV exposure times in comparison to bone marrow stem cell, periodontal ligament cell,
smooth muscle and endothelial cell lineages. Moreover osteoblasts cultured at 39 oC did
not deteriorate in terms of alkaline phosphatase expression or calcium deposition within
the extracellular matrix (ECM), but did reduce cell proliferation. We believe however that
the lower proliferation diminished osteoblast sensitivity to UV and the photoinitiator. In
fact, the relative survivability of osteoblasts was found to be augmented by the combination
of a biochemical factor and an elevated incubation temperature; specifically, the use of 50
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mg/L of the anti-oxidant, ascorbic acid significantly (P<0.05) increased the survivability
of osteoblasts when cultured at 39 oC. We conclude that ascorbic acid at an incubation
temperature of 39 oC can be included in in vitro protocols used to assess cartilage
integration with bone ECM. Such inclusion will enhance conditions of the engineered
tissue model system in recapitulating in vivo osteoblast activity.
Keywords: Cytotoxicity, osteoblasts, ascorbic acid, photoinitiator, photopolymerizable
hydrogels

3.2 Introduction
Tissue engineering has been emerging as the potential approach to restoring and enhancing
tissue or organ function in the health care industry [1, 2]. In the musculoskeletal arena,
photopolymerizable hydrogel approaches are thought to offer several advantages, namely
that the geometry of defects to be filled with de novo tissue can be arbitrary, delivery may
be carried out via injection [3] thus permitting minimal invasiveness and finally, hydrogel
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materials are considerably less expensive than biodegradable fibrous scaffolds thus
presenting a more cost effective procedure. In brief, a polymer mixture in monomer form
is prepared, with a very low concentration of photoinitiator (0.02 to 0.05 % w/v) [4]; cells
are suspended within the solution and the mixture is subsequently injected into the repair
site. Next, the monomer solution is exposed to ultraviolet light (UV) at low intensity (45mW/cm2) during which free radicals initiate polymerization [5]. Despite their critical
function, the highly mobile free radicals cause a number of adverse effects such as damage
to extracellular proteins as well as cell apoptosis and necrosis events [6, 7, 8].
Our long term goal is to provide better anchorage and fixation between tissue engineered
cartilage and the underlying subchondral bone for the treatment of mild to modest
osteoarthritis, using a reliable engineered tissue model system for bone and cartilage. This
system requires a reasonable degree of survivability of osteoblasts so that integration can
occur. Previous experiments including our own experience suggests that osteoblasts
ordinarily do not survive well under combined ultraviolet light and photoinitiator
environments [90]. This may explain the limited success that has been achieved thus far
in co-relation of in vitro to in vivo results and the successful integration of engineered
cartilage to bone in vitro [10].
Cartilage integration involves the following two challenges: first, the scaffold that is used
initially must be harmonized in the joint; secondly, the ensuing developing tissue must
anchor with the underlying bone to provide a strong fixation. We note that none of the
existing techniques in cartilage tissue engineering have been able to restore a sustained
articular surface because subchondral bone integration to de novo cartilage tissue via
osteoblast activity at the interface has to date, not been sufficiently addressed [11]. Thus,
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the main objective of this study was to determine how the detrimental effects of
photopolymerization parameters to human osteoblast survivability could be minimized
while still permitting sufficient gelation. Primarily, these parameters were ultraviolet light
(UV) exposure time and photoinitiator concentration. In addition, we included in this effort,
four additional human cell sources as a means of comparison. Since our focus was targeted
on osteoblasts which are traditionally known to be cultured at relatively lower temperatures
o

(34 C) [12], we also examined the role of in vitro temperature incubation on osteoblast
viability. Finally, we focused our efforts on the utility of the antioxidant, ascorbic acid on
augmenting the survivability of the osteoblasts.
3.3 Material and Methods
3.3.1 Cell Culture
Five different cell lines were culture expanded and comparatively evaluated as a function
of varying UV intensities and photoinitiator concentrations:
3.3.1.1 Human Bone marrow derived Mesenchymal Stem Cells (HBMSCs)
HBMSCs are a well characterized population of adult stem cells that can differentiate into
other cell lines to produce cartilage, bone, fat and muscle tissue. HBMSCs (Science cell,
Carlsbad, CA, USA) were seeded onto Poly D-lysine coated T-75 flasks (Fisher Scientific,
Pittsburg, PA, USA). The cells were cultured until passage 3 (P3) in low glucose media
(Dulbecco’s modified eagle medium, (DMEM), Invitrogen, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum ((FBS), ATCC, Manassas, VA, USA ) and 1%
penicillin–streptomycin (ATCC).
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3.3.1.2 Human Pulmonary Artery Endothelial Cells (HPAEC)
HPAECs (Fisher Scientific) were seeded in T-75 flasks with proprietary endothelial cell
growth medium (Fischer Scientific) and culture expanded to P4.
3.3.1.3 Human Pulmonary Artery Smooth Muscle Cells (HPASMC)
Human Pulmonary Artery Smooth Muscle Cells (HPASMC) (Genlantis, San Diego, CA,
USA ) were cultured (up to P4) in T-75 flasks (Fisher Scientific) in proprietary smooth
muscle cell growth medium (Genlantis).
3.3.1.4 Human Osteoblasts (hFOB)
Human Osteoblasts (hFOB 1.19) (ATCC) were

cultured (passage number was not

provided by the depositor) in basal media (Invitrogen) supplemented with 10% FBS
(ATCC), 1% Penstrep (ATCC) and 0.3mg/ml of an aminoglycoside antibiotic (Sigma
Aldrich, St Louis, MO, USA)
3.3.1.5 Human periodontal ligament cells (HPDLCs)
HPDLCs (P3) were received as a gift from the University of Miami, FL (Dr. Herman
Cheung). The cells were cultured in basal media (up to P3) supplemented with 10% FBS
(ATCC), 1% Penstrep (ATCC).
3.3.2 Effect of UV light at different exposure times
In order to study the effect of UV exposure times on the cells, a cell solution (105 cells/ml)
was prepared for each cell type; 200µl was subsequently placed in each well of a 96 tissue
culture well plate providing a final density of 20,000 cells/ well. Cells (N = 4 /group) were
exposed to 4-5mW/cm2 of long wave unfiltered UV light (365 nm) for time durations of 0,
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5, 10, 15 and 20 minutes. These time intervals were chosen to provide adequate dynamic
range of exposure times. After exposing the wells to different time intervals, the plates
were incubated at 37 oC and 5% CO2 humidified environment for 2 days.
3.3.3 Effect of Photoinitiator concentration on different cell lines
We used the commercially available photoinitiator, Irgacure 2959 (BASF Corporation,
Florham Park, New Jersey, USA) given its extensive usage in tissue engineering research
studies [13, 14], and it’s relatively less toxic effect on cells. [8, 9] .Three concentrations
were prepared: 0, 0.03% and 0.05 w/v ratios. Briefly, 50mg and 100 mg of Irgacure 2959
were dissolved in 1ml of 70% ethanol solution. The contents were sterilized using 0.2μm
syringe filters and subsequently, 6μl/ml and 5μl/ml of the solutions were added into 1ml of
cell solution respectively to give the eventual desired w/v ratios of 0.03% and 0.05%. Cells
were seeded in the 96 well plate as described in the UV exposure experiments (N =
4/group). The two different concentrations of photoinitiator were added in each of the
respective groups and placed in an incubator for 2 days. Cells without photoinitiator
exposure served as controls.
3.3.4 Combined effects of UV exposure times and Photoinitiator concentration
The five different cell lines (BMSCs, HPAEC, HPASMC, hFOB 1.19, PDLCs ) were
exposed to combined Photoinitiator (0.05% w/v ratio) and long wave UV light for different
time durations of 0, 5, 10, 15 and 20 minutes. Well plates were housed in an incubator for
2 days to permit cell growth.
3.3.5 Effect of incubation Temperature
We assessed the effect of incubator temperature on osteoblasts owing to the sensitivity of
this cell type to this parameter. Osteoblasts were cultured in three 96 well plates. Wells in
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the 96 well plate were grouped into 4 wells and each group was treated with both UV light
exposure of 10 minutes and photoinitiator concentration as 0.05% w/v ratio. The wells
without any treatment (N=4) acted as control. All samples were kept at 3 different
incubation temperatures of 34o,37o and 39 oC for 48 hours and maintained at 5% CO2 in a
humidified environment.
3.3.5.1 Effect of temperature on the osteoblast phenotype
3.3.5.1.1 Alkaline Phosphatase Activity
The matrix maturation phase of osteoblasts is characterized by maximal expression of
alkaline phosphatase (ALP) and once the mineralization is complete in the matrix, calcium
deposits can be visualized in the extracellular matrix (ECM). In order to assess ALP
activity (n = 3 samples/group), osteoblasts were plated using the same media conditions as
before (section 1.1) at 37 oC and 39 oC, via a colorimetric based assay (Abcam, Cambridge,
MA, USA). After 3 days of culture, 20,000 cells were taken for each sample and were lysed
in 100µl of assay buffer. Lysed cells were subsequently centrifuged at 13,000 g for 3
minutes to remove the insoluble material. 30 µl of sample was taken in replicates of 3 for
each sample in 96 well plates. Next, 50 µl of sample of assay buffer was added to make a
net volume of 80µl in the wells. In addition, background samples were made by taking 30
µl of test samples, and adding 50 µl of assay buffer and 20 µl of stop solution. Thereafter,
50µ of 5mM p-nitrophenyl phosphate solution was added to each well containing the test
samples and background samples. The samples were covered to prevent exposure to light
and the reaction and held at 25 oC for 1hr. Next the reaction was halted by the addition of
10µl stop solution (Abcam) to each well (except to the background samples) and gently
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shaken. The optical density was measured per manufacturer instructions using a microplate
reader (wavelength of 405 nm; model Synergy HT, Biotek Instruments, Winooski, VT).
3.3.5.1.2 Calcium Distribution
As an indicator of the osteoblast maturation process during cell culture, sample calcium
mineral distribution was evaluated using von-Kossa histological staining (IHCWORLD,
Woodstock, MD, USA). In brief, 20,000 cells/ml were grown on chamber slides (Fisher
Scientific) and kept at the two different temperatures (37 oC and 39 oC) using the same
media conditions as before (section 1.1). After 3 days the slides were washed with
phosphate buffered solution and were fixed with 10% formalin (Fisher Scientific). Finally,
the von-Kossa stain (IHC world, Woodstock, MD, USA) was applied by treating the slides
with silver nitrate solution and exposing them to UV light for 1 hour, which served to
highlight spatial locations of calcium deposits in the specimens.
3.3.6 Effect of using anti-oxidants
In order to assess the benefits of anti-oxidant incorporation on osteoblast survival rate, we
used 50 mg/ml of ascorbic acid in our cell culture system. Photoinitiator concentrations of
0.05% w/v ratio were added into the selected wells. Ascorbic acid was added to the wells
(N=4) and exposed to long wave UV light for 10 minutes. Plates were incubated at three
different temperatures of 34 oC, 37 oC and 39 oC for 2 days
3.3.7 Cytotoxicity evaluation using sulforhodamine B (SRB) assay
At the conclusion of each of the aforementioned experiments, a sulforhodamine B (SRB)
assay (Sigma Aldrich) was performed to access cytotoxic effects of UV exposure times
and photoinitiator concentrations on the different cells. The SRB assay is a measure of cell
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cytoxicity as a function of proliferation rate of the surviving cells. The assay was performed
similar to assays conducted previously [15]. In brief, the assay is based on the measurement
of viable cellular protein content in the cells colorimetrically [16]. Cells were first fixed to
the bottom of a well plate with 10% (wt/vol) trichloroacetic acid. After the cells were fixed,
Sulforhoda-mine-B (SRB) dye was added for cell staining at a concentration of 0.4%
(wt/vol) which bound to viable cellular proteins. Next, 1% (vol/vol) acetic acid was used
to remove the unbound SRB dye. 10 mM Trizma-base was used then to extract the protein
bound SRB. The optical density (OD) of the dye was measured [17] at 565 nm wavelength
using a micro plate reader (Biotek, Winooski, VT). Comparisons were made between
control and treated samples.

A higher OD value would translate to increased cell

proliferation. Cell cytotoxicity was reported based on ‘‘Relative Survival’’ which was
determined from the absorbance values (n = 4 samples/group) measured. For reporting
purposes, a normalization process was carried out similar to previous studies [9]. In brief,
results were normalized such that the average absorbance of the control groups was equal
to one; first, the average absorbance of the background wells that contained only the
specific cell culture medium and the SRB dye were subtracted from each of the individual
absorbance values. Next, normalization was performed by dividing each of the absorbance
values by the average absorbances of the corresponding control group of cells, without any
exposure to UV and photo initiator, but otherwise grown under identical culture conditions.
3.3.8 Statistical Analysis
Statistical analysis was performed using commercially available software (SPSS, IBM,
version 20, Armonk, New York, USA). A one way ANOVA and post-hoc Tukey test was
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used to determine statistical significance (P < 0.05) between groups in all experiments
conducted.
3.4 Results
3.4.1 Effect of UV light at different exposure times
The human cell sources investigated showed altered viability after exposures to UV light
(4-5 mW/cm2) (Fig. 3.1). The periodontal ligament cells were the most resistant to UV
exposure. On the other hand, the Osteoblast survival rate considereably decreased,
particularly after > 10 minutes of UV exposure.
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Figure 3.1: Cell toxicity results for different human cell sources after different UV exposure
times. Cells were incubated at 37 oC

3.4.2 Effect of Photoinitiator Concentration
Fig. 3.2 demonstrates the survival rate of 5 different cell lines with different concentrations
of photoinitiator (irgacure 2959; 0, 0.03% and 0.05%) and without UV exposure. In
general, the effect of photoinitiator alone had little effect on the different cell types.

Figure 3.2 Cell toxicity results for different human cell sources incubated at 37 oC for 48 hours
after exposure to different photoinitiator concentrations

3.4.3 Combined effect of UV exposure and Photoinitiator
The effect of combined UV exposure and a photoinitiator concentration of 0.05% (w/v)
were assessed. This amount of photoinitiator concentration was chosen as it is very
commonly used and reported in the literature [13, 14, 18]. The general trend was that of
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exaggerated decrease in survivability in all five cell types studied (Fig. 3.3) in comparison
to UV exposure alone (Fig. 3.1). Our findings further suggested that osteoblasts cells were
the least tolerant to the combined effect of UV light and Photoinitiator, ranging at ~ 17%
for 10 minutes of UV exposure and only 6% at 20 minutes.

Figure 3.3: Cell toxicity results for different human cell sources after exposure to different UV
exposure time concentrations and a fixed photoinitiator concentration of 0.05% (w/v).Cells were
incubated at 37 oC. Note that osteoblast relative survivability was significantly reduced (P <
0.05) at all UV exposure times shown in comparison with all the other cell types that were
investigated

3.4.4 Effect of incubation temperature
After obtaining baseline information on the variability of osteoblast viability on UV
exposure times and photoinitiator concentrations in comparison to other human cell
sources, we proceeded to focus on further improving osteoblast survivability within the
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framework of commonly utilized parameters in injectable photopolymerizable hydrogels.
Namely these were UV exposure times of 10 minutes and a photoinitiator concentration of
0.05% (w/v) [14, 18, 19]. We speculate that these numbers were chosen not only to ensure
sufficient live cell numbers, but also to ensure sufficient gelation of the hydrogels. Human
osteoblast survivability under these conditions was approximately 17%. These experiments
were conducted at 37 oC and we proceeded to augment it to 39 oC. At this higher
temperature, a 5% increase in osteoblast survivability was observed (Fig. 3.4)

Figure 3.4: Cell toxicity results for human osteoblasts as a function of incubator temperature.
Cells were exposed for a total of 10 minutes under UV light and using a fixed photoinitiator
concentration of 0.05% (w/v). The “*” indicates that the difference between the groups was
statistically significant (P<0.05).
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3.4.5 Effect of Adding Ascorbic Acid
When, 50 mg/L of ascorbic acid was added to the cultured cells, incubated at 39 oC, we
found that the osteoblast viability improved to ~ 34%, an increase of 13% in comparison
to cultures grown at identical conditions but without the antioxidant (Fig 3.5). The
differences in normalized relative survivability (mean ± standard deviation) for osteoblasts
culture with and without ascorbic acid antioxidant at 39 oC incubation temperature was
found to be significant (P < 0.05) (Table 3.1).

Figure 3.5: Survivability of osteoblasts with and without ascorbic acid. The “*” indicates that the
difference between the groups was statistically significant (P<0.05)
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Table 3.1: Osteoblast Relative Survivability with and without Ascorbic Acid antioxidant at 37 oC
and 39 oC incubation temperatures
Groups exposed to 0.05% w/v photoinitiatior concentration and Average Standard
10 minutes of UV exposure; (n = 4 samples/group)
deviation
37 degrees alone

0.17

0.02

37 degrees + ascorbic acid

0.23

0.01

39 degree alone

0.22

0.01

39 degree + ascorbic acid

0.34

0.02

3.5 Discussion
In the past decade considerable efforts have focused on utilizing polymerizable
scaffolds for tissue engineering [20, 21, 22, 23, 24]. In this context, the effects of UV
exposure and photoinitiator concentrations on cell viability have always been a concern,
but none more so than for osteoblasts which are extremely sensitive to ultraviolet light [9].
Accordingly, we attempted to augment the survivability of human osteoblasts in these
environments by exploring additional variables, namely, a higher incubation temperature
and incorporation of the antioxidant, ascorbic acid. These changes may serve to improve
photopolymerizable approaches in bone tissue engineering and outcomes related to nativeengineered tissue integration approaches [24, 25]. In this regard, on-going research efforts
in our laboratories are specifically attempting to target an approach to more successfully
integrate subchondral bone to tissue engineered cartilage constructs.
Osteoblasts were significantly reduced in survivability (P < 0.05) compared to all
the other four human cell types (PDLCs, HPASMCs, HPAECs and BMSCs) investigated
at all-time durations of UV exposure (5, 10, 15 and 20 minutes) when in concomitant 0.05
% w/v photoinitiator environments. These results confirmed that human osteoblasts were
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considerably more prone to cell necrosis under combined UV light exposure and photo
initiator concentrations. When osteoblasts were exposed to commonly utilized parameters
of 10 minutes of UV exposure and a 0.05% (w/v) concentration of photoinitiator (Irgacure
2959, BASF Corporation, Florham Park, New Jersey), contrary to reports of using a
relatively low incubation temperature of 34 oC for rapid cell division [26, 27] in our case,
this lower temperature actually decreased cell viability. In fact, we were able to further
ameliorate osteoblast survivability under these environments (combined 10 minutes of UV
exposure and 0.05% (w/v) photoinitiator concentration) at an elevated temperature of 39
o

C, suggesting thus, that for photopolymerization studies, osteoblasts require relatively

higher, rather than reduced incubation temperatures. We proceeded to conduct statistical
analysis on temperature effects of osteoblast survivability and noted that temperature alone
at 39 oC augmented the cellular viability significantly (P<0.05) in comparison to lower
incubation temperatures (34 oC and 37 oC) (Fig.3.4). This result illustrates the importance
of this elevated temperature as a singular independent entity in promoting osteoblast
viability. Meanwhile, anti-oxidation effects of ascorbic acid minimized free radical toxicity
effects during UV polymerization and was found to be consistent with use of ascorbic acid
elsewhere [28, 29, 30]. When ascorbic acid was combined with incubation temperatures
at 39oC, osteoblast survivability was further enhanced significantly (P < 0.05), (Fig. 3.5);
(normalized average ± standard deviation (n = 4 samples/group) osteoblast survivability
for: i) 37 oC without ascorbic acid: 0.17 ± 0.02 ii) ascorbic acid at 37oC: 0.23 ± 0.01, iii)
elevated temperature of 39 oC without ascorbic acid: 0.22 ± 0.01, iv) ascorbic acid at 39oC:
0.34 ± 0.02). We speculate that the increased osteoblast survivability at the higher
temperature of 39 oC can be attributed to a reduction in the proliferation rate of the cells.
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For example, Williams et al [9] showed that higher proliferation rates caused greater cell
susceptibility to toxic components in photopolymerization environments (i.e., (UV and
photoinitiator) and thereby resulted in decreased cellular viability. Interestingly, use of
either ascorbic acid or the 39 oC incubation temperature promoted roughly the same level
of osteoblast survivability. However, we have for the first time demonstrated that the
combined effects of ascorbic acid at a concentration of 50 mg/L and an elevated incubation
of 39 oC significantly improves (P< 0.05) augmentation of osteoblast survival versus using
only one of either of these two parameters (Fig. 3.5).
Under these conditions, although the UV and photoinitator environments still
considerably reduce human osteoblast survivability (owing to the innate sensitivity of
osteoblasts to any changes to in vitro culture parameters) [9] in comparison to controls
grown in more standard environments, we note that we still were able to maintain ~ 34%
survivability; this is considerably greater than other osteoblast groups in our studies, as
well as those that have been reported elsewhere [9]. In addition, we note that average
osteoblast-like cell densities in osteoinductive environments are in the order of roughly
240,000 cells/cm2 [310] whereas photopolymerizable tissue engineering studies use ~
850,000 cells/cm2 [32, 33]. Even though 850,000 cells/cm2 is closer to the higher end of
amounts typically used, the 34% reduction (290,000 cells/cm2) is still the same order of
magnitude as osteoblast-like cell densities [240,000 cells/cm2, [31] thought to be indicative
of heightened osteoblast activity. Thus, in spite of the greater sensitivity of osteoblasts to
UV exposure time and photoinitiator concentrations, the addition of ascorbic acid during
UV and photoinitiator exposure at an incubation temperature of 39oC would retain
sufficient live osteoblast numbers that in turn, would allow for an elevated level of cellular

42

activity (e.g. such as osteoinduction). We noted however that an incubation temperature
of 39 oC could potentially aggravate osteoblast ALP-activity and/or ECM-mineral
distribution, and thus, we proceeded to look at Alkaline Phosphatase (ALP) expression and
the presence of calcium deposits at 37 oC versus 39 oC. We determined that ALP
expression (Average ± standard deviation; n = 3 samples/group) was in the order of 2.26 ±
0.12 U/ml and 2.00 ± 0.06 U/ml for cells cultured at 37 oC versus 39 oC for 3 days. We
believe that the relatively lower expression at 39 oC is due to the lower proliferation rate of
the osteoblasts that we observed during the cell culture studies at this temperature.
However the expression magnitudes at both temperatures are comparable to literature
reports for ALP activity from osteoblasts that underwent similar (but not identical) cell
culture, and which was found to be in the order of 2.23 ± 0.14 U/ml [34]. Overall therefore,
we believe our findings for osteoblasts cultured at 39 oC while relatively lower than that at
37 oC, was due to the slower proliferation rate rather than a result of the cells being
adversely affected.
We also assessed elevated temperature effects on the ability of the osteoblasts to
synthesize calcium primarily because crystalline salts deposited in the matrix of bone are
composed principally of calcium and phosphate, which are combined to form
hydroxyapatite crystals and an indicator of healthy cellular activity. We confirmed that as
observed during cell culture studies that at 39 oC, proliferation rate was affected and lesser
cell numbers were seen after 3 days of cell culture. However calcium mineral deposition
was clearly visualized in regions surrounding cells in both the 37 oC and 39 oC conditions
(Fig. 3.6), thereby providing preliminary evidence that the ability of osteoblasts to produce
calcium is not affected at 39 oC.
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Figure 3.6: Von-Kossa staining conducted at 37 oC and 39 oC after 3 days of osteoblast culture.
Osteoblasts appear as elongated structures staining red while blue arrows point to examples of
calcium deposited by the osteoblasts, which stain black. Osteoblast proliferation rate was
observed to be slower at 39 oC. On the other hand, this slower rate improved relative
survivability of the cells, because high proliferation rates have shown to make cells more
vulnerable to toxic effects (UV and photoinitiator concentrations) present in photopolymerized
environments [9]

It is important to point out that the intended application of our findings is not in the clinic
as cartilage tissue engineering is still an emerging field as indicated by several leading
groups in the area [35, 36, 37]; rather, these conditions can readily be used in in vitro
engineered cartilage tissue model systems where injectable hydrogels are being actively
experimented with [38, 39, 40, 41, 42]. The benefit of incorporating our findings is that
controlled in vitro experiments to assess integration studies for engineered cartilage to bone
extracellular matrix can be achieved without compromising osteoblast activity, a critical
component to the integration process, prior to progressing to more variable in vivo models.
3.6 Conclusions
In conclusion, for studies involving cellular photopolymerization protocols, we have
demonstrated that significant improvement (P < 0.05) of human osteoblasts in situ are
possible by combined usage of an increased incubation temperature of 39 oC and the use
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of ascorbic acid at a concentration of 50mg/L. We speculate that further improvements to
osteoblast survivability may be possible by fine tuning the ascorbic acid concentration
further and/or with the use of additional antioxidants such as uric acid and Beta-Carotene.
A limitation of our approach was that we conducted our investigations in monolayer culture
as opposed to 3-Dimensional (3-D) matrices, such as hydrogels. However, we expect our
results to represent a “worst case scenario” since the UV environments which severely
diminishes osteoblast viability was introduced by means of direct exposure, while in the
case of tissue engineered 3-D constructs, cells remain suspended within a gel or scaffold
material, thus offering some level of protection.

We therefore recommend the

implementation of the enhanced osteoblast culture parameters found herein for cellular
experiments that involve photopolymerizable materials.
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Chapter 4
Improvements in Integration of Engineered Cartilage to Bone Matrix Using
Hydroxyapatite
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This chapter describes the interaction of engineered cartilage to an engineered bone system
with and without hydroxyapatite (HA) environments, specifically over the spatial transition
zone between the two materials. Through a systematic series of mechanical, biochemical,
cellular and histological outcomes, we present compelling evidence here suggesting that
HA significantly improves integration of engineered cartilage to a bone matrix.
4.1 Abstract
Articular cartilage injuries occur frequently in the knee joint. Photopolymerizable cartilage
tissue engineering approaches appear promising; however, fundamentally, forming a stable
interface between the subchondral bone and tissue engineered cartilage components
remains a major challenge. We investigated the utility of hydroxyapatite (HA)
nanoparticles to promote controlled bone-growth across the bone-cartilage interface in an
in vitro engineered tissue model system using bone marrow derived stem cells. Samples
incorporated with HA demonstrated significantly higher interfacial shear strength (at the
junction between engineered cartilage and engineered bone) compared to the constructs
without HA (p < 0.05), after 28 days of culture. Interestingly, this increased interfacial
shear strength due to the presence of HA was observed as early as 7 days and appeared to
have sustained itself for an additional three weeks without interacting with strength
increases attributable to subsequent secretion of engineered tissue matrix. Histological
evidence showed that there was ~7.5 % bone in-growth into the cartilage region from the
bone side. The mechanism of enhanced engineered cartilage to bone integration with HA
incorporation appeared to be facilitated by the deposition of calcium phosphate in the
transition zone. These findings indicate that controlled bone in-growth using HA
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incorporation permits more stable anchorage of the injectable hydrogel-based engineered
cartilage construct via augmented integration between bone and cartilage.
4.2 Introduction
Articular cartilage defects and lesions are one of the most common injuries that occur in
the knee joint[1,2]. Curl et al, [1] demonstrated in their study of consecutive knee
arthroscopies that up to 63% of the patients with knee-related symptoms suffered from
chondral or osteochondral defects [3]. These defects may also progress to osteoarthritis if
left untreated [4], which further involves degradation of articular cartilage, the subchondral
bone, the synovial capsule and membrane as well as the periarticular tissues [5]. Patients
suffering from cartilage lesions and other degenerative cartilage diseases currently have
limited treatment options available. One technique that is often used clinically to treat these
defects is autologous chondrocyte transplantation (ACT); however there is no significant
evidence that this approach yields superior results compared to standard treatment of care,
such as with physical therapy and anti-inflammatory medication [6,7]. Furthermore, ACT
has limited applicability as in some cases, when there is no intact cartilage rim, the covering
of the chondrocyte suspension with a periosteal flap or a collagen sheet is often insecure
restricting the usage of this technique to only certain types of injuries [2].
A possible solution lies in tissue engineering strategies for cartilage repair. It involves the
implantation of a biological scaffold in the defect that would degrade over a period of time
and promote tissue repair within the defect space [8]. However, one major problem is the
lack of retention of the tissue engineered cartilage. Scaffolds need to be retained during the
majority of the regenerative process at their implantation site in order for the treatment
strategy to be successful. For this to occur, a stable anchor for the scaffold is required which
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will prevent it from being dislodged. Previous studies have taken approaches based on the
principles of mechanical [9-12], chemical [13-15] and biological fixation [16-18] in order
to form novel strategies of integration, but have demonstrated limited success in terms of
scaffold retention within the defect for the entire duration of the tissue repair process, which
can extend up to 4 weeks [19]. Another limitation with the cartilage transplantation is the
lack of its integration with the host tissue. Lane et al [20], showed that after a 6 month
period there was no integration between the host and osteochondral plug that was inserted
into fixed articular cartilage defects. Similarly, there were other studies [21,22] that showed
a lack of integration between the engineered cartilage and host tissues.
In cartilage tissue engineering, injectable hydrogels have shown great potential as scaffold
support structures. With their similarity to the water content in biological tissues, hydrogels
have been used extensively for tissue engineering applications. They can be injected at
room temperature and will take the form of the defect during low-intensity ultraviolet (UV)
photopolymerization. Thus, they offer a great advantage over fibrous scaffold approaches,
particularly for the treatment of small to medium sized focal osteochondral defects arising
from injury or mild to moderate osteoarthritis. In the generalized treatment approach,
initiation of bleeding through bone microfracture will cause human bone marrow derived
stem cells (HBMSCs) to migrate to the defect space. UV-initiated gelation will cause the
monomer hydrogel solution, which would have been already pre-treated with chondrogenic
factors (e.g. transforming growth factors such as TGFβ), to cross link, thereby
encapsulating the cells [23]. Very likely, the surgical procedure will be relatively straight
forward, short in duration and potentially minimally invasive. However, even though
photopolymerizable hydrogel approaches have demonstrated great potential in cartilage
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tissue engineering, there is still a need to tailor enhanced mechanical stability; that would
lead to the retention of the engineered tissue construct at the implant location so that de
novo cartilage can be formed under optimal conditions, i.e., with the hydrogel scaffold still
remaining within the defect space. In order to accomplish this, in this study, we used
hydroxyapatite (HA) nanoparticles, to promote controlled bone in-growth from the ventral
bone location to the dorsal cell-encapsulated, injectable hydrogel location in an in vitro
engineered tissue model system, so that enhanced anchorage of the engineered cartilage
could be achieved via a stronger interface.
4.3 Material and methods
4.3.1 Overview
An in vitro bone and cartilage model was created using osteoblast-seeded Agar scaffolds
and HBMSC-seeded photo polymerizable poly (ethylene glycol) diacrylate, respectively.
The main focus of the study was to evaluate the effect of HA on augmenting integration
between the bone and cartilage layers as a function of time. Experimental time points were:
Day 1, Day 7, Day 14 and Day 28. Outcomes were assessed via cell viability, biochemical
assays (Sulfated Glycosaminoglycans (sGAGs), DNA, Alkaline Phosphatase), histology
and RT-PCR. Finally, direct mechanical testing was performed at the bulk and interface
scale using compression and shear tests
4.3.2 Cell Culture
4.3.2.1 Human Bone marrow derived Mesenchymal Stem Cells (HBMSCs)
HBMSCs (Science cell, Carlsbad, CA, USA) were seeded onto Poly D-lysine coated T- 75
flasks (Fisher Scientific, Pittsburg, PA, USA). Characterization of HBMSCs was
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confirmed by the supplier via positive immunostaining for CD73, CD105 and particularly,
CD 90 (Thy-1) a stem cell marker [24]. After stem cell differentiation, lipid staining was
also confirmed. Additional characterization of these HBMSCs showed that they retain their
phenotype in cell culture for up to 15 cell doubling cycles and therefore remained stable
for the duration of our cell culture experiments in which expansion continued for up to 6
cell doubling periods. The cells were cultured in low glucose media (Dulbecco’s modified
eagle medium, (DMEM), Life Technologies, Grand Island, NY, USA) supplemented with
10% fetal bovine serum ((FBS), ATCC, Manassas, VA, USA ) and 1% penicillin–
streptomycin (ATCC), per manufacturer’s recommendations [25], until passage 3 (P3).
4.3.2.2 Human Osteoblasts (hFOBs)
The hFOBs (hFOB 1.19,ATCC) were cultured in basal media (Catalog #: 11039-021; Life
Technologies) which consisted of 1:1 mixture of DMEM and Ham's F-12, and included
Lglutamine (2.5mM) and HEPES (15.01mM). We additionally supplemented the basal
media with 10% FBS (ATCC), 1% Penstrep (ATCC) and 0.3mg/ml of an aminoglycoside
antibiotic (Catalog #: G8168, Sigma Aldrich, St Louis, MO, USA). The hFOBs from the
supplier (ATCC) were originally transfected from discarded limb tissue [26] to create an
immortalized cell line; upon arrival to our laboratory, the cells were culture expanded until
passage 4 (P4).
4.3.3 Tissue Engineering Experiments
4.3.3.1 Tissue Engineered Bone
Engineered bone was prepared using 2% Agar scaffold [27] in which osteoblast cells were
encapsulated. Briefly, 2.5 % of Agar solution (Fischer Scientific) was prepared and heated
to a temperature of 70oC. Meanwhile, osteoblasts were trypsinzed and 20 million cells were
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dissolved in 200 µl of cell media (Same as media utilized in hFOB cell culture; Catalog
#1039021; Life Technologies). Once the Agar solution started to boil, it was removed from
the hot plate and allowed to cool in a room temperature environment. When the temperature
reached 40oC, 64 µl of Agar solution was mixed with 16 µl of cell suspension and were
cast for 5 minutes in custom designed molds (5mm in diameter and 4.1 mm in length) at
room temperature. Each gel construct consisted of a 2% Agar solution with a suspension
of ~1.6 million osteoblasts and at this juncture, remained immersed in the media used to
culture the osteoblasts.
4.3.3.2 Tissue Engineered Cartilage
Engineered Cartilage was prepared using 15% PEGDA solution with 0.5% w/v HA. This
concentration was chosen after preliminary testing established that it yielded a good
compromise between robust cell viability and a strong potential for effective tissue
integration through osteoinduction (Data not shown). A 15% w/v PEGDA solution was
prepared by dissolving 150 mg of PEGDA powder (Glycosan Biosystems, Salt Lake City,
UT) and 5 mg of HA nanoparticles (Catalog # 677418, Sigma Aldrich) in Phosphate buffer
saline (PBS) (Sigma Aldrich). The protocol for hydrogel preparation with the exception of
the incorporation of HA nanoparticles was very similar to that previously reported by Durst
et al [28] and Yang et al [29]. Each HA nanoparticle was characterized by a < 200 nm
particle size, a surface area > 9 m2/g by the supplier (Sigma-Aldrich) and has been used
previously for bone substitute studies [30,31]. Subsequently, 100 mg/ml of photoinitiator
solution (Irgacure 2959, Ciba Specialty Chemicals, Tarytown, NY) in 70% ethanol was
constituted and added to the monomer solution (5μl/ml), followed by thorough stirring.
This resulted in a 0.05% w/v ratio of the photo initiator concentration. HBMSC's at a
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concentration of 20 million cells/ml were introduced just prior to UV exposure. Next, the
solution was irradiated with UV light at 4-5 mW/cm2 for 7 minutes to induce
polymerization. We previously established that HBMSC viability was unaffected by the
UV intensity and exposure timescales utilized here [32].
After the respective engineered cartilage and bone segments were prepared, the former was
placed on top of the latter construct. Subsequently, they were both physically held together
with a thin stainless steel pin (Fischer Scientific, Catalog # 26002-10) that was pierced
through both the layers. Each of these 2 layer constructs were transferred into a well (in a
24 well plate), with each well containing 1 ml of chondrogenic media (Fisher Scientific,
Catalog # SH3088902); the samples were then incubated in a humidified environment at
37oC and 5% CO2. This chondrogenic media was so-called because it contains proprietary
growth factors from the supplier (Fisher Scientific) to direct differentiation of HBMSCs to
chondrocytes [33]. Constructs were similarly made with cells but without hydroxyapatite
in them i.e., the constructs without HA. In addition, acellular controls with and without
hydroxyapatite particles were also made in the similar fashion. In sum, four groups were
ultimately prepared: Group 1: PEGDA No HBMSC-No HA; Group 2: PEGDA-HA No
HBMSC; Group 3: HBMSC encapsulated in PEGDA No HA and finally Group 4: HBMSC
encapsulated in PEGDA-HA. Groups were cultured for 7, 14 and 28 days.
4.3.4 Cell Viability
A Live-Dead assay using Calcein AM/Ethidium homodimer (Life Technologies) staining
to assess the viability of cells [34] within the constructs was conducted following the
manufacturer's protocol on osteoblasts-encapsulated Agar constructs as well as on
HBMSC-encapsulated in PEGDA (Group 3) and HBMSC-encapsulated in PEGDA-HA
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(Group 4) samples; Briefly, samples from different group at different time points (Day1,
Day 7, Day 14 and Day 28) were cut using a blade to a thickness of 1 mm and then were
stained with Calcein AM and Ethidium homodimer in PBS solution and incubated for 30
minutes. Next, they were washed 3 times with PBS solution to remove the background
fluorescence and subsequently visualized under the fluorescent microscope (Olympus
IX81, Olympus America Inc., Miami FL) at excitation and emission wavelengths of 468nm
and 568nm respectively. Images of the samples were taken with each image encompassing
an area of 4.32 mm2. A mean ± standard deviation (SD) of percentage (%) cell viability
was subsequently computed at the different time points by counting cells on representative
images (ImageJ software, NIH, Bethesda, MD) and calculating the ratio of live cells (green
dots) to the sum of live and dead cells (red dots) and finally, multiplying by a 100% (n =3
images/group/time point).
4.3.5 Glycosaminoglycan and DNA Characterization
The wet weight of the constructs were initially obtained, and then followed by the dry
weight after 48 hours of lyophilization of the constructs [35] for each group (n=3
samples/group) per time point. The dried constructs were crushed using a tissue grinder
and digested in 1ml of papain digest solution (0.2M sodium phosphate buffer pH 6.5, 0.1M
sodium acetate, 0.01M EDTA, 0.005M cysteine HCl, and 2 mg of papain lyophilized
crystals/10ml extraction buffer) for 16 hours at 65oC. Sulfated Glycosaminoglycan
(sGAGs) concentration was determined by using dimethylmethylene blue dye [36]
(Biocolor, Blyscan Glycosaminoglycan Assay, County Antrim, UK). Once the samples
were digested in papain, 100 µl of the sample was taken and mixed with 1 ml of dye in a
mechanical

shaker

for

30

minutes.

During
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this

time

period,

a

sulphated

glycosaminoglycan-dye complex was formed and precipitated out from the soluble
unbound dye when centrifuged for 10 minutes. The precipitate was then dissolved in the
dissociation agent, and absorbance at 565 nm was measured using a microplate reader
(Biotek) and compared with known, standard solutions of chondroitin 4-sulfate (Biocolor)
to calculate the sGAG values. Specifically, dilution of a sterile solution of bovine tracheal
chondroitin 4-sulfate (100 µg/ml; Biocolor) with de-ionized water was performed to obtain
the following six known standard concentrations of sGAG: 0, 0.1, 0.2, 0.33,4,5 µg/ml
chondroitin 4-sulfate. Final presentation of sGAG concentrations were normalized with
respect to the sample dry weight (μg/mg dry weight).
The papain-based digestion protocol for the DNA assay was identical to the sGAG assay
described earlier. The DNA content in the constructs was calculated using the Quant-iT™
PicoGreen dsDNA kit (Life Technologies) as in previously described studies [37]. Samples
were incubated with the Quant-iT™ PicoGreen reagent for 2-5 minutes, and then the
fluorescence was measured at an excitation and emission of 485nm and 520nm,
respectively, using a microplate reader (Synergy HT, Biotek, Winooski, VT). Fluorescence
values measured from the DNA assay were converted to DNA based on fluorescence
measured from known standard DNA concentrations. Known standard concentrations were
obtained by dilution of a stock DNA solution provided by the manufacturer (Lambda DNA,
Biocolor). The stock DNA solution was diluted in a buffer (10 mM Tris-HCl, 1 mM EDTA,
pH 7.5) to obtain the following five concentrations of DNA solution: blank (0 pg/ml),
25pg/ml, 250pg/ml. 2.5ng/ml and 25ng/ml. A standard curve was plotted after the
fluorescence of the known DNA concentrations was measured and subsequently, this curve
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was used to convert the fluorescence-derived signal of the tissue engineered constructs to
DNA concentrations.
4.3.6 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
To confirm the chondrogenic phenotype of differentiated HBMSCs in PEGDA and to
verify the possibility of undesirable expression of bone markers in the tissue engineered
cartilage in the presence of HA, quantitative real time-polymerase chain reaction (qRTPCR) was performed on the samples of HBMSC's encapsulated in PEGDA in HBMSC
media, HBMSC's encapsulated in PEDGA in chondrogenic media and HBMSC's
encapsulated in PEGDA-HA in chondrogenic media, after 4 weeks of culture in their
respective media. Total mRNA was extracted for each group using the SV total RNA
isolation kit (Promega, Madison, WI). First, 3 samples from each group were crushed and
pooled into 1 and subsequently, the RNA isolation procedure was followed as described
by the manufacturer (Promega). Next, 5µg of mRNA was used for the reverse transcriptase
reaction as previously established [37, 38]. The mRNA for 3 groups was converted into
cDNA using the GoScript_Reverse Transcription kit (Promega). The cDNA was
synthesized using an oligo(dT) primer, according to the manufacturer’s instructions. The
qRT-PCR was performed using the GoTaq qPCR Master Mix (Promega). The PCR tubes
contained forward and reverse primers and SYBR green I dye reagent along with the
cDNA, which was obtained during reverse transcription. The primers (Table 1) were
designed using the Basic Local Alignment Search Tool (BLAST) program, National Center
for Biotechnology Information (NCBI) to amplify the target sequences. Step-One RealTime PCR System (Life Technologies) was used to detect the signals when the mixture
was followed by thermal cycling conditions per manufacturer’s instructions (Promega).
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Finally, the expression of the following markers: GAPDH, SOX9, aggrecan, collagen II,
osteocalcin, scleraxis were measured for the different groups. Finally, the change in cycle
threshold (Cт) values were averaged and normalized with GAPDH using the ΔΔCт method
[39]. Fold changes were calculated as 2- ΔCт, and the gene expression ratio of each of the
three groups was plotted.
Table 4.1: Quantitative RT-Polymerase Chain Reaction primer sequences used in this study
Genes

Forward Primer

Reverse Primer

GAPDH

AATGAAGGGGTCATTGATGG

AAGGTGAAGGTCGGAGTCAA

SOX9

GTAATCCGGGTGGTCCTTCT

GTACCCGCACTTGCACAAC

Aggrecan

GCGAGTTGTCATGGTCTGAA

TTCTTGGAGAAGGGAGTCCA

Collagen II

AGACTTGCGTCTACCCCAATC GCAGGCGTAGGAAGGTCATC

Osteocalcin

CACTCCTCGCCCTATTGGC

CCCTCCTGCTTGGACACACAAAG

4.3.7 Mineralization Assessment:
Mineralization of the 2 layer constructs (n=3 samples/group) at the interface was quantified
using a colorimetric based assay qualitatively via an Alkaline Phosphatase (ALP) Assay
kit (Abcam, Cambridge, MA, USA). Samples were cut from the interface 1 mm from each
side, and then were homogenized in the assay buffer. The samples were then added to pnitrophenyl phosphate (p-NPP) and incubated for 60 minutes at 25oC. Next, stop solution
from the kit was added to arrest hydrolysis of p-NPP to p-nitrophenol. The optical density
was then measured using a microplate reader set to a wavelength at 405nm (Synergy HT,
BioTek, Winooski, VT) to measure the level of released p-nitrophenol. Results were

61

presented as enzyme specific activity per volume of sample solution (enzyme units per liter
(U/L)).
Mineral distribution on the 2 layer constructs was evaluated using the Von-Kossa
and Alcian Blue Stain kit (IHC world, Woodstock, MD, USA). Staining was performed
such that simultaneous visualization of both bone and cartilage matrix deposition could be
observed on the same tissue section. Briefly the sectioned samples were first treated with
silver nitrate solution and exposed to UV light for 60 minutes and then with Alcian Blue
stain. Sections (25µm) were then washed with distilled water and observed under a
microscope.
Tissue fill quantification:
Representative histological images were analyzed to quantify the % of engineered tissue
in the transition zone, defined as the region between the engineered bone to engineered
cartilage layers (ImageJ). First the entire area of the cartilage region was measured and
next, the transition zone areas were computed (ImageJ). The transition zone area as a % of
the entire cartilage area was subsequently calculated to reflect the % filling of tissue within
the transition zone. In addition, for the constructs with HA, the calcium deposits as a % of
the transition zone area was also computed. This enabled a determination of the % tissue
in the transition zone that was exclusively filled by engineered bone-derived calcium
phosphate matrix, at the conclusion of 4-weeks.
4.3.8 Mechanical Properties
4.3.8.1 Compression
Scaffold mechanical properties were determined by performing unconfined static
compression testing on the constructs (n=3 samples/group) using a mechanical testing
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device (Bose, Eden Prairie, MN) with a displacement rate of 0.05 mm/sec. The
experimental group for compression testing consisted of HBMSC-encapsulated in PEGDA
(Group 3) and HBMSC encapsulated in PEGDA-HA (Group 4), whereas the control groups
included osteoblasts in Agar, as well as corresponding acellular controls for PEGDA
(Group 1) and PEGDA-HA (Group 2). Tests were conducted on samples at Day 1, Day 7,
Day 14, and Day 28 for all 5 groups. Briefly, the diameter of each tissue engineered
construct was initially measured using a vernier caliper. Next, the constructs were placed
between the flat metal platens and the load was recorded at 0.05 mm increments using a
displacement rate of 0.05 mm/sec. Corresponding stress and strain were subsequently
computed. The compressive modulus was taken to be the slope in the initial linear region
of the stress-strain curve [40].
4.3.8.2 Shear
The interfacial shear stress between the PEGDA-based, tissue engineered cartilage and the
Agar-based bone substrate was determined by performing a shear test at the interface
location of the 2 layers. For each 2 layer group, Agar with osteoblast-HBMSCencapsulated in PEGDA (Group 5) and Agar with osteoblast-HBMSC-encapsulated in
PEGDA-HA (Group 6)), (n = 6 samples/group) samples to be tested for each time point
were placed horizontally on the platen on an individual basis. One side of the sample was
affixed with super glue to the lower platen. The other side of the sample was similarly
glued to the upper platen. Then the upper platen was increased in height with a
displacement rate of 0.05 mm/sec with load-displacement data recorded simultaneously at
every 0.003 mm displacement. The test was arrested when the 2 layers separated from each
other and there was a sudden decrease in the load.
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4.3.9 Statistics
Statistical analyses of the results obtained from the biochemical, DNA and ALP assays as
well as from the cell viability and mechanical testing experiments were performed using
commercially available software (SPSS, IBM, version 20, Armonk, NY, USA). A one way
ANOVA and post hoc Tukey test was used to compare means and to determine statistically
significant differences (p < 0.05) between groups respectively. In cases where only two
groups were compared, the one way ANOVA simply reduced to a t-test for independent
groups.
4.4 Results
4.4.1 Cell Viability
The viability of the cells in the engineered scaffolds was observed over a period of 28 days
at 4 time points (Day 1, Day 7, Day 14 and Day 28). At 28 days, Osteoblasts remained very
viable in the Agar gel (Fig. 4.1 a and Table 4.2).

Figure 4.1 (a): Live Dead assay over a 4 week period for Osteoblasts in agar scaffold. Images
clearly showed that cells remained viable over this time frame with a much larger density of live
(green dots) versus dead (red dots) cells.

Similarly, HBMSCs were also found to be very viable within the PEGDA environments
without HA (Fig. 4.1 (b) and Table 4.2).
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Figure 4.1 (b): Live Dead assay over a 4 week period for HBMSCs in PEGDA. Images clearly
showed that cells remained viable over this time frame with a much larger density of live (green
dots) versus dead (red dots) cells.

The incorporation of HA into the PEGDA hydrogels did produce relatively lower cell
counts compared to samples without HA (p < 0.05). However it should be noted that the
clustering of cells in the vicinity of HA particles resulted in enlargement of the green
intensity regions (Fig. 1c) thereby very likely underestimating the number of live cells in
the PEGDA with HA group. In spite of this ~ 65% of cells were found to be viable at 28
days (Table 2).

Figure 4.1 (c): Live Dead assay over a 4 week period for HBMSCs in PEGDA-HA. Images
clearly showed that cells remained viable over this time frame with a much larger density of live
(green dots) versus dead (red dots) cells.
Table 4.2: Quantitative assessment of percentage cell viability in samples subjected to the livedead assay

Sample

Day 1

Day 7

Day 14

Day 28

Agar
osteoblast

77.96 ± 1.19

78.72 ± 0.70

81.86 ± 0.30

83.42± 0.47
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PEGDA with
HBMSC

74.53 ± 0.90

75.46 ± 0.50

93.55 ± 0.95

91.94± 1.02

PEGDA HA
with HBMSC

73.47 ± 0.94

65.83 ±0.76

69.97 ± 0.75

73.84 ± 0.42

4.4.2 Glycosaminoglycan and DNA Characterization
Proteoglycan deposition in both HBMSC-seeded scaffolds (PEGDA and PEGDA-HA)
increased over a period of 4 weeks. At day 1, both scaffolds had similar amounts of sGAGs
deposition; at 28 days no statistically significant difference (p > 0.05) in sGAGs could be
detected between the cellular scaffolds regardless of whether HA was utilized or not (Fig.
4.2). It was observed however that the sGAG concentration for PEGDA constructs was
5.64 ± 0.98



found to be 6.78 ± 0.15

, while for PEGDA-HA constructs the sGAGs concentration was


after 4 weeks.
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Figure 4.2: S-GAG content in HBMSC seeded-PEGDA and PEGDA-HA constructs. The “*”
indicates that the difference between the groups was statistically significant (p < 0.05)

The DNA content for HBMSC cellular PEGDA constructs remained relatively unchanged
temporally. On the other hand, similar samples with the incorporation of HA showed a
significant increase (p < 0.05) in DNA content (Fig. 4.3).

67

Figure 4.3: DNA concentration of HBMSC encapsulated in PEGDA and PEGDA HA scaffolds.
The “*” indicates that the difference between the groups was statistically significant (p < 0.05)

4.4.3 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
It was observed that after culturing the constructs in chondrogenic media for 28 days, there
was an increase in the Aggrecan, Sox 9, and Type II collagen gene expression of the
BMSCs, indicative of chondrogenic differentiation of the HBMSCs. It was also observed
that the HBMSCs encapsulated in PEGDA-HA constructs showed minimal increase in
expression of bone marker osteocalcin and minimal decrease in Type II collagen
expression (Fig. 4.4). Overall, HBMSCs encapsulated in PEGDA-HA showed similar
expression of these genes compared to the non-HA counterparts.
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Figure 4.4: qRT-PCR of HBMSC grown over a period of 4 weeks in BMSC media and
chondrogenic media. Results indicate that cells exposed to HA underwent similar chondrogenic
differentiation to unexposed counterparts

4.4.4 Mineralization
The mineralization at the interface of the 2 layer, cellular PEGDA-Agar structures was
determined using the ALP assay. The results (Mean ± SD; U/L) are summarized as follows:
Day 1 - PEGDA without HA: 0.2 ± 0.02; PEGDA with HA: 0.22 ± 0.09; Day 14 - PEGDA
without HA: 1.12 ± 0.29; PEGDA with HA: 2.2 ± 0.10; Day 28 - PEGDA without HA: 2.1
± 0.16; PEGDA with HA: 5.2 ± 0.25. The interface with HA exhibited higher ALP activity
(p < 0.05) when compared to the constructs without HA at the end of a 4 week duration
(Fig. 4.5 a). Confirmation of the enhanced mineralization under HA environments was
additionally evidenced by histology using the Von-Kossa staining at the interface,
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specifically in the form of positive staining for calcium phosphate matrix (black staining;
Fig. 4.5 (b)).
No evidence of calcium phosphate was evident in the histology of samples without HA
(Fig. 4.5 (b)). In addition, without the use of HA, the gap between engineered cartilage and
bone decreased only negligibly beyond two-weeks (by an additional 1% of original gap
area). On the other hand, histological image analysis determined that calcium phosphate
matrix comprised roughly 7.5% of the entire cartilage area when HA was incorporated in
the engineered constructs. Moreover, when HA was incorporated, the interfacial gap
between engineered cartilage to engineered bone was found be filled with tissue with ~
53% and 90% filling at 2 and 4 weeks respectively. Roughly 66% (area within the white
dots; Fig. 4. 5(b)) of the transition zone (sum of areas within the white and yellow dots;
Fig. 4.5(b)) comprised of calcium phosphate deposits after 4 weeks.

Figure 4.5 (a): ALP Activity using colorimetric method. The “*” indicates that the difference
between the groups was statistically significant (p < 0.05).
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Figure 4.5 (b): Von Kossa - Alcin Blue histology images of 2 layer constructs. Above: Agar
osteoblast and PEGDA-HBMSC and Below: Agar osteoblast PEGDA-HA-HBMSC. Results
showed that there was an increase in ALP activity at day 28 for the tissue engineered cartilage
exposed to HA nanoparticles. The histological findings (Fig. 4.5(b)) confirmed the colorimetric
assessment of ALP activity (Fig 4.5(a)). The boundary of the transition zone was traced as
indicated by the dotted yellow lines. At Day 1, a clear gap was apparent between the engineered
cartilage and bone regions. Progressive filling of the transition zone subsequently occurred with
calcium phosphate matrix deposits (black staining). At week 2, roughly 53% of the initial area of
the transition zone was filled by the deposit in constructs with HA. By week 4, ~ 90% of the
transition zone was filled in constructs with HA while it was ~70% filled in the constructs
without HA. White dotted line indicates the bone in growth into the cartilage region. Area
measurements were made using Image analysis software (ImageJ, NIH, Bethesda, MD).

4.4.5 Mechanical Properties
The Young's modulus of the acellular and cellular scaffolds of all groups (acellular:
PEGDA ± HA; cellular: HBMSC-seeded PEGDA ± HA) was assessed using unconfined
static compression testing. The results revealed no significant differences after 28 days (p
> 0.05) between the acellular groups. Similarly, the cellular groups exhibited comparable
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stiffness properties between each other (p > 0.05). However, there was a statistically
significant difference (p < 0.05) in the temporal evolution of the Young's modulus of
cellular samples grown, which increased over the 4 weeks (Fig. 4.6).

The integration between engineered bone and cartilage constructs was assessed using
mechanical shear loading and it was found that there was a statistically significant (p<0.05)
difference in the integration strength between the groups when compared at both 1 week
and at 4 weeks of tissue culture, i.e., Agar with osteoblast-HBMSC-encapsulated in
PEGDA and Agar with osteoblast-HBMSC-encapsulated in PEGDA-HA. Furthermore, the
shear strength of Agar with osteoblast-HBMSC-encapsulated in PEGDA-HA was
significantly higher than the Agar with osteoblast-HBMSC-encapsulated in PEGDA-only
at 4 weeks (p <0.05). At 28 days, the mean ± SD shear strength for the group that
incorporated HA exhibited shear strength in the order of: 5.91 ± 0.59 kPa while in the
constructs without HA it was found to be: 3.60 ± 0.11 kPa (Fig. 7). The % increase in
interfacial shear strength after addition of HA at 28 days was found
Figure 4.6: Compression test results. The “*” indicates that the difference between the groups
was statistically significant (p < 0.05). Results showed that the presence of HA in acellular
PEGDA and tissue engineered cartilage did not affect the mechanical integrity of PEGDA as well
as that of the tissue engineered cartilage. There was a significant increase (p < 0.05) in the
Young's modulus in the cellular groups when comparing Day 1 to Day 28. This demonstrated
increased engineered tissue formation over 4 weeks resulting in increased stiffness of the cellular
constructs.

The integration between engineered bone and cartilage constructs was assessed using
mechanical shear loading and it was found that there was a statistically significant (p<0.05)
difference in the integration strength between the groups when compared at both 1 week
and at 4 weeks of tissue culture, i.e., Agar with osteoblast-HBMSC-encapsulated in
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PEGDA and Agar with osteoblast-HBMSC-encapsulated in PEGDA-HA. Furthermore, the
shear strength of Agar with osteoblast-HBMSC-encapsulated in PEGDA-HA was
significantly higher than the Agar with osteoblast-HBMSC-encapsulated in PEGDA-only
at 4 weeks (p <0.05). At 28 days, the mean ± SD shear strength for the group that
incorporated HA exhibited shear strength in the order of: 5.91 ± 0.59 kPa while in the
constructs without HA it was found to be: 3.60 ± 0.11 kPa (Fig. 4.7).

Figure 4.7: Shear Testing Results. The “*” indicates that the difference between the groups was
statistically significant (p < 0.05). Results showed that there was enhanced integration with bone
at day 28 compared to day 1 in both groups evaluated. However, there was a significant increase
in tissue integration at day 28 when HA was present showing its importance in enhancing the
anchorage of tissue engineered cartilage to bone
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The % increase in interfacial shear strength after addition of HA at 28 days was found to
be 64%. Meanwhile, the % temporal increase in interfacial shear strength of samples
cultured from 7 to 28 days differed negligibly between the with and without HA groups
(over this timeframe, samples without HA increased by 99% whereas in HA-incorporated
samples, it was found to be 101%). We note in addition however that there was already a
~ 62 % increase in the interfacial shear strength of samples with HA inclusion after only 7
days of tissue culture and therefore was comparable to the augmentation in strength that
was found after 28 days (64%).
4.5 Discussion
The use of injectable hydrogels to support chondral and osteochondral cartilage filling has
been extensively investigated over the past 15 years. Some prominent works are
summarized here: Elisseeff et al [41] used an injectable hydrogel approach for the creation
of neocartilage in vivo which could be implemented via a transdermal photopolymerization
approach. Another study used a new class of injectable hydrogels derived from watersoluble chitosan and oxidized hyaluronic acid [42] which was highly amenable for cartilage
tissue engineering applications. Guo et al [43] fabricated an injectable hydrogel bilayered
construct in vivo to mimic the osteochondral layer. Another group, Nettles et al [44],
suggested the use of another type of injectable elastin like polypeptide for the use of
cartilage repair in vivo.
The overall consensus after meticulous in vivo studies was that lack of integration between
hydrogel and host tissue yielded inconsistent levels of cartilage filling and repair. Some
efforts to ameliorate the integration have been followed by various groups using
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mechanical, chemical or biological fixation [45]. For example, screws [46] and sutures [10]
have been utilized previously to mechanical affix engineered cartilage to subchondral bone.
Wang et al [16] demonstrated that chondroitin sulphate methacrylate could be used as an
engineered cartilage to bone adhesive by demonstrating stable and durable fixation over a
period of 5 weeks; however, further investigations were needed to demonstrate a
consistently successfully outcome. Elsewhere, Hoemann et al [17] indicated that Chitosan
glycerol phosphate when mixed with blood in the cartilage defect space not only formed
greatly improved integration with sub-chondral bone, but also resulted in enhanced hyaline
cartilage tissue formation. Indeed, in vivo (primarily in the rabbit model) cartilage tissue
engineering studies have shown convincing bone marrow stem cell migratory responses
towards the ostechondral interface and subsequent tissue remodeling when chitosan was
utilized [47,48].
With a persistent lack of conclusive success in effective integration, the objective of this
study was to evaluate the use of hydroxyapatite (HA) in nano particulate form, to promote
the integration between tissue engineered cartilage grown in an injectable hydrogel
substrate, to bone extracellular matrix (ECM). HA nanoparticles were found to settle at the
inferior end of the cylindrical hydrogel specimens. Under these HA-rich environments, we
determined first that the HBMSC viability and proliferation remained stable. Further, the
cells exhibited chondrogenic differentiation in PEGDA+ HA environments through robust
expression of articular cartilage genes, Aggrecan, Sox-9 and type II collagen (Fig. 4). Upon
verification that HA was safe to incorporate within the PEGDA hydrogels, we proceeded
with investigations on mechanical properties and integration effectiveness of PEGDA+ HA
based engineered cartilage to bone ECM. Interfacial shear stress was significantly
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increased when HA was used (p < 0.05; Fig. 8). Histological findings demonstrated
traversing of the PEGDA to Bone interface with the creation and a distinct presence of a
calcium phosphate-rich transition zone (Fig. 5b).
The incorporation of HA in an injectable photopolymerizable system was able to provide
an enhanced anchorage of engineered cartilage to bone ECM; to our knowledge we are the
first to demonstrate this finding in photopolymerizable hydrogels. However, other
laboratories have attempted to augment the interfacial mechanical properties of engineered
cartilage and subchondral bone using biomaterials such as chitosan particles [48], porous
calcium polyphosphate [49], chitosan-chondroitin sulfate [50]. One group even used HA
in conjunction with non-photopolymerizable alginate hydrogels and reported on its shear
mechanical properties [18,51]. As data was reported as shear moduli [18], we first
computed the shear moduli of our PEGDA-HA constructs at 14 and 28 days in the linear
region of the mean stress-strain curve (n = 6 samples; curve not shown), which persisted
up to ~ 5% strain. The computed shear moduli from Khanarian et al [18] was ~ 1.8 and 3.5
kPa at 14 and 28 days respectively, whereas we found the shear moduli for the PEGDAHA samples to be in the order of 33.6 ± 1.9 kPa at 14 days and 40.2 ± 3.7 kPA at 28 days
(n = 6 samples/group). This evaluation indicates that the shear moduli determined here is
an order of magnitude large than other reports in the literature on osteochondral scaffold
shear properties which incorporated HA. However, it should be noted that this is not a
direct comparison because shear properties were measured using a rheometer [18], whereas
we assessed shearing properties at the interface of engineered cartilage and engineered
bone. Interestingly, we found that the benefit of HA incorporation was seen as early as
after 7 days of culture at which point there was already a substantial increase in interfacial
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shear strength (by ~ 62%) in comparison to corresponding samples without HA (Fig. 7).
The presence of HA had a negligible effect on the subsequent % temporal increase in
interfacial shear strength between 7 and 28 days of tissue culture (% increase in samples
with HA: 101% and in samples without HA: 99%). As a result, at 28 days, there was similar
% interfacial shear strength improvement in the samples with HA versus the samples
without HA (by ~ 64%) in comparison to the corresponding % increase observed at 7 days
(by 62%). This finding suggests that HA augments the interfacial shear strength of
engineered cartilage to engineered bone constructs during the early, i.e., the first week of
tissue development, and this benefit carries forward beyond this period in a relatively
unaffected manner. From a translational standpoint, the incorporation of HA for
osteochondral repair will thus have a pronounced effect in terms of the interfacial shear
strength of the tissue engineered cartilage construct to the subchondral bone during the
early stages (first 7 days) following treatment, after which standard tissue integration
process will continue, likely unaltered. Thus, future in vivo studies in cartilage tissue
engineering that will incorporate HA into their development protocol could likely assess
maximum interfacial shear strength improvement of engineered cartilage to host bone
tissue that is directly attributable to HA, as early as 1 week following implantation.
Alkaline phosphatase activity was found to be higher in the groups when HA was used.
Histological studies also demonstrated controlled growth of calcium phosphate deposits at
the interface. We interpret that the augmented calcium phosphate deposits were due to
migration of osteoblasts from the bone ECM to the inferior region of the tissue engineered
cartilage layer that ultimately led to the creation of a transition zone; again this was directly
attributable to the presence of HA particles at the interface. However it is important to note
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that the transition zone characterized by calcium phosphate, i.e., bone-related ECM
occupied ~ 7.5 % of the total cartilage region, whereas the rest of this area was rich in
engineered cartilage tissue. Thus, in the context of osteochondral defects we anticipate that
the majority of the space would still be filled by cartilaginous tissue, except for an ingrowth of calcium phosphate from subchondral bone (promoted by HA nanoparticles),
which would thereby assist in securing the engineered cartilage construct in-place. Indeed,
histological evidence suggested that a temporal narrowing of the interfacial gap between
engineered cartilage to bone progressively occurred over 4 weeks when HA was used (~
53% and 90% filling at 2 and 4 weeks respectively), via the creation of a transition zone,
primarily characterized by calcium phosphate ECM deposits (Fig. 6b). The incorporation
of HA in the engineered constructs permitted ~ 66% of the transition zone to be comprised
of calcium phosphate deposits after 4 weeks. Conversely a calcium phosphate-rich
transition zone was absent when HA was not utilized. In addition, in the constructs without
HA, the gap between engineered cartilage and bone decreased only negligibly beyond twoweeks (by an additional 1% of original gap area) demonstrating that in an in vitro
framework, tissue filling of the transition zone can be enhanced during extended culture
periods (> 2 weeks) using HA nanoparticles. Recently St. Pierre et al [49], reported that
the presence of a calcified zone at the osteochondral junction augmented the interfacial
shear strength by ~ 3.3 times in comparison to when a calcified matrix was absent. Taking
this finding in the context of our study, HA may have initiated sparse calcium phosphate
deposition in the transition zone during the early stages of tissue culture (1 week) which
contributed to the increase in interfacial shear strength.
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Even though our results with HA appear promising, our model was restricted to in vitro,
static processes and did not mimic in vivo physiological loading states or interactions from
surrounding such as the synovial fluid. Secondly, the cells utilized were from healthy
sources, yet very frequently osteochondral and chondral defects are common in individuals
who have mild to moderate disease states such as osteoarthritis. We are currently
examining the effect of disease on our proposed approaches of integration effectiveness
utilizing HA. Finally, even though significant improvement in integration strength with
HA was observed (p < 0.05), the critical strength needed for effective cartilage tissue repair
and regeneration outcomes clinically has not been identified. In addition native human
cartilage to bone failure shear strength has been reported to be at least three orders of
magnitudes higher (~ 7.25 MPa) [52]. Thus, whether or not the improvements found in the
constructs with HA will translate into enhanced cartilage repair in vivo still remains to be
proven.
Nonetheless, we in summary demonstrated that the significant improvement (p < 0.05) in
the integration strength of tissue engineered cartilage with underlying engineered bone can
be obtained with the use of hydroxyapatite nanoparticles, which aggregate at the inferior
end of the injectable photopolymerizable hydrogels. The process of interfacial shear
strength improvement between engineered cartilage to engineered bone constructs seems
to have occurred during the early tissue culture period (first 7 days), and this increase
carried forward to extended durations (up to 28 days) without interaction with the
subsequent intrinsic augmentation in strength due to de novo tissue formation processes.
The mechanism of improved integration and as a consequence, enhanced anchorage of the
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engineered cartilage constructs appeared to be due to the osteoblast secretion of calcium
phosphate deposits, induced by the presence of HA.
Meanwhile, the bulk of the engineered cartilage region still consisted of de novo tissue
formation rich in cartilage ECM. We therefore propose the incorporation of HA
nanoparticles as a means to enhance the integration of engineered cartilage to subchondral
bone in future photopolymerizable hydrogel-based cartilage tissue engineering studies.
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Chapter 5
Improvement in integration of engineered cartilage with native cartilage matrix in
healthy and diseased state

This chapter describes the interaction of engineered cartilage to a healthy and diseased
mimics of cartilage in HA rich environments. This chapter provides evidence that the
incorporation of HA can be beneficial for enhancing the integration of a tissue engineered
scaffold to a defect space even if the native cartilage has become diseased.
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5.1 Abstract
We previously reported that Hydroxyapatite (HA) nanoparticles promote engineered
cartilage to bone matrix integration. In the present study, using a similar approach, we
investigated the effectiveness of integrating tissue engineered cartilage derived from
human bone marrow derived stem cells (HBMSCs) to healthy as well as osteoarthritic
cartilage mimics in an in vitro engineered tissue model system. We found that there was a
statistically significant (p<0.05) higher shear strength in the tissue engineered cartilage
from HBMSCs without HA particles which was integrated with healthy chondrocytederived cartilage matrix as compared to the corresponding counterparts with HA. However
we found the opposite effect in osteoarthritic environments, wherein the HBMSC-derived
cartilage integrated with cartilage matrix with HA particles exhibited a significantly higher
(p<0.05) interfacial shear strength as compared to when HA was not incorporated;
histological evidence subsequently confirmed that a distinct spatial transition zone, rich in
calcium phosphate deposits, is likely to have attributed to this higher interfacial strength.
These findings collectively point towards an important role for HA nanoparticles in treating
osteochondral defects when osteoarthritis is a co-morbidity. We speculate that the calcified
layer formation at the interface in the osteoarthritic environment in the presence of HA is
due to similarities in gene expression in this diseased state in comparison to bone matrix.
5.2 Introduction
Articular cartilage lesions in the knee frequently occur following an injury. Curl et
al [1] demonstrated that up to 63% out of a total of 31514 knee arthroscopies suffered from
chondral lesions. Another study by Hjelle et al [2], found that 61% out of 1000 knee
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arthroscopies had chondral or osteochondral lesions. Ultimately, an absence of an intrinsic
healing capacity in chondrocytes prevents it from permitting complete restoration of the
lost tissue. With limited treatment options, the sustained presence of cartilage defects may
lead to the onset of osteoarthritis [3-5], which will accelerate the tissue loss. Numerous
studies have been done [6, 7] to treat articular cartilage defects in the knee but none of them
have been able to provide consistently favorable outcomes.
Tissue engineering approaches have been shown to hold great promise for treating
cartilage defects. Tissue engineering generally involves the implantation of a
biodegradable scaffold within the defect space that will degrade over time and
concomitantly, it will support tissue repair/regeneration processes, initiated by cells present
within the defect space [8]. Since the knee is highly mobile, an added prerequisite for
cartilage tissue engineering is the retention of new cartilage within the defect, i.e., the
scaffold would need to be retained in the defect site during the early phases of the
regenerative process to promote sufficient tissue filling. We note that such retention would
not only require effective integration of de novo cartilage with the underlying subchondral
bone (in the case of osteochondral defects), but in addition, would also need to integrate
well with surrounding native cartilage tissues. To permit such integration, previous studies
have utilized approaches based on the principles of mechanical [9-12], chemical [13-15]
and biological fixation [16-18]. While these investigations were promising, consistent
success was again lacking.
Recently, injectable hydrogels incorporating hydroxyapatite (HA) nanoparticles
have shown great potential in enhancing the integration of engineered cartilage to bone
matrix [18, 19]. The targeted treatment was intended for small to medium sized
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osteochondral defects (< 50 mm2) that could arise either from an injury and/or from mild
to moderate levels of osteoarthritis [20]. In addition, our recent experience suggested that
HA directly promoted enhanced integration of the engineered cartilage to the bone matrix
by the creation of an intermediate calcium phosphate rich transition zone, thereby
permitting greater stability of the implant [19]. We note that previous studies have
described that a graded transition in material properties between two different tissue
matrices is an indicator of integration effectiveness [21]. However, as described earlier,
complete spatial integration must require fusion of the engineered cartilage to the
surrounding native cartilage as well, and not only to bone. This is particularly the case in
chondral defects where the surrounding native tissue is characterized completely by
articular cartilage. In this context, here, we report on the utility of HA nanoparticles in
promoting the integration between engineered cartilage derived from human bone marrow
mesenchymal stem cells (HBMSCs) with the chondral matrix secreted by healthy (HCs)
human chondrocytes (HCs). The experiments were subsequently repeated with human
osteoarthritic chondrocytes (HCOAs) in place of the HCs, so as to understand the impact
of this diseased state on cartilage-cartilage integration processes, in considering that some
level of osteoarthritis is usually present in knee articular cartilage, containing injuryinduced defects [22].
5.3 Material and methods
5.3.1 Overview
An in vitro healthy and diseased engineered cartilage model system originating
from human chondrocytes was integrated with HBMSC-derived cartilaginous engineered
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matrix and evaluated after 28 days of growth. The cartilage matrix from the chondrocytes
was prepared using agar scaffolds that encapsulated in a segregated manner, the healthy
and osteoarthritic chondrocytes populations. Meanwhile the HBMSCs were seeded onto
photopolymerizable poly (ethylene glycol) diacrylate (PEGDA). Assessment was
conducted in terms of viability, mechanical testing, histological and gene expression at the
following time points: Day 1, Day 7, Day 14 and Day 28.
5.3.2 Cell Culture
5.3.2.1 Human Bone marrow derived Mesenchymal Stem Cells (HBMSCs)
HBMSCs (Science cell, Carlsbad, CA, USA) were seeded onto Poly D-lysine
coated T-75 flasks (Fisher Scientific, Pittsburg, PA, USA). The cells were cultured in
manufacturer supplied proprietary medium (AdvanceSTEM Mesenchymal Stem Cell
Expansion Kit (Thermo Scientific, Waltham, WA) until passage three (P3).
5.3.2.2 Healthy Human Chondrocytes (HC)
HCs (Cell Applications Inc., San Diego, CA, USA) were sourced from nonpathologic articular cartilage. They were cryopreserved at passage 2 (P2) when shipped by
the manufacturer. When the cells were received, they were plated in T-75 flasks (Fisher
Scientific, Pittsburgh, PA, USA) and allowed to proliferate. The cells were cultured in the
Human Chondrocyte Media (Cell Applications, San Deigo, CA) until P4 and were
subsequently used for the experiments.
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5.3.2.3 Human Chondrocytes-Osteoarthritis (HCOA)
HCOA (Cell Applications) were isolated from the articular cartilage from patients
with Osteoarthritis. They were received from the manufacturer at P1 and prior to usage in
the experiments, they were cultured, and propagated in the human chondrocyte media (Cell
Applications) until P4.
5.3.3 Tissue Engineered Healthy Cartilage
Engineered healthy cartilage was prepared using 2% Agar scaffold [23] in which
adult chondrocytes were encapsulated. 2.5 % of Agar solution (Fischer Scientific) was
prepared and heated to a temperature of 70oC. Meanwhile, chondrocytes were trypsinzed
and 20 million cells were dissolved in 200µl of cell media. Once the Agar solution started
to boil, it was removed from the hot plate and allowed to cool in a room temperature
environment. When the temperature reached 40oC, 64 µl of Agar solution was mixed with
16 µl of cell suspension and casted for 5 minutes in custom designed molds (5mm in
diameter and 4.1 mm in length) at the room temperature. Each gel construct consisted of a
2% Agar solution with a cellular suspension consisting of ~1.6 million chondrocytes.
5.3.4 Tissue Engineered Diseased Cartilage
Tissue engineered osteoarthritic cartilage was prepared in the same manner as tissue
engineered healthy cartilage except for the use of HCOAs instead of HCs.
5.3.5 Stem-Cell derived Tissue Engineered Cartilage
BMSC derived engineered cartilage was prepared using our previously established
protocols [19]. Briefly, the constructs were fabricated using 15% PEGDA solution with a
0.5 % w/v HA. 15% PEGDA solution was prepared by dissolving 150 mg of PEGDA
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powder obtained from Glycosan Biosystems ( Salt Lake city, UT) and 5 mg of HA
nanoparticles (Catalog # 677418, Sigma Aldrich) in 1 ml Phosphate buffer saline (PBS)
(Sigma Aldrich). Subsequently, 100 mg/ml of photoinitiator solution (Irgacure 2959, Ciba
Specialty Chemicals, Tarrytown, NY) in 70% ethanol was added to the monomer solution
in a concentration of (5μl/ml) to get a final concentration of 0.05% w/v of photo initiator.
HBMSCs were introduced just prior to UV exposure at a concentration of 20 million
cells/ml. Next, to induce polymerization, the solution was irradiated with UV light at 4-5
mW/cm2 for 7 minutes that we previously demonstrated did not antagonize the viability
of the cells [24].
Once the chondrocyte-derived HC and HCOA engineered cartilage segments were
prepared, samples of engineered cartilage matrix secreted from HBMSCs were positioned
on top of the chondrocyte-based constructs, i.e., either healthy or osteoarthritic, to mimic
adjacent healthy and diseased native articular cartilage environments respectively. The
two-layered constructs were subsequently physically held together with a thin stainless
steel pin (Fischer Scientific, Catalog # 26002-10) that was pierced through both the layers.
The two layer constructs were transferred to 24-well plates, and supplied with 1 ml of
chondrogenic media per sample (Fisher Scientific, Catalog # SH3088902) that were then
incubated in a standard cell culture incubator operating under 95% air, 5% CO2, 37oC and
humidified conditions.
Cellular constructs were similarly made without HA. In sum, four groups of 2 layers
specimens were ultimately prepared as follows: 1) HCs encapsulated in Agar-HBMSCs
encapsulated in PEGDA without HA 2) HCs encapsulated in Agar-HBMSCs encapsulated
in PEGDA with HA, 3) HCOAs encapsulated in Agar-HBMSCs encapsulated in PEGDA
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without HA, and 4) HCOAs encapsulated in Agar-HBMSCs encapsulated in PEGDA with
HA.
5.3.6 Cell Viability
To assess the viability of HCs and HCOAs encapsulated in Agar constructs as well
the HBMSCs encapsulated in PEGDA constructs with and without HA, a Live-Dead assay
was conducted using Calcein AM/Ethidium homodimer (Life Technologies, Carlsbad, CA)
staining following the manufacturer's protocol.
In brief, 1 mm sections from the different groups were grown to different time
points (Day1, Day 7, Day 14 and Day 28) and were cut using a blade and subsequently
stained with Calcein AM and Ethidium homodimer in PBS solution and incubated for 30
minutes. Next, to remove the background fluorescence they were washed 3 times with PBS
solution and then visualized under a fluorescent microscope (Olympus IX81, Olympus
America Inc., Miami, FL) at excitation and emission wavelengths of 495/515 nm and
495/635 nm for Calcein AM and Ethidium homodimer respectively. Viability of HBMSCs
in PEGDA environment with and without the incorporation of HA was previously reported
by our research group [19].
5.3.7 Mechanical Testing
The interfacial shear strength between the PEGDA-based tissue engineered
cartilage and the agar based healthy (or alternatively, diseased) engineered cartilage
substrates were determined by performing shear testing at the interface of the 2 layers.
Samples to be tested (n =6/group) were placed horizontally on the platens. One side of the
sample was adhered to the upper platen while the other end was secured to the lower platen,
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both using super glue. The upper platen was subsequently displaced at a rate of 0.05
mm/sec with data logging conducted at every 0.03 mm of displacement. The test was ended
when the 2 layers were observed to separate from each other that were also accompanied
with a sudden rapid decrease in the loads recorded.
5.3.8 Histology
Calcium and GAG matrix distribution at the interface of two layer constructs for
Group 1-4 specifically 1) HCs encapsulated in Agar-HBMSCs encapsulated in PEGDA
without HA 2) HCs encapsulated in Agar-HBMSCs encapsulated in PEGDA with HA, 3)
HCOAs encapsulated in Agar-HBMSCs encapsulated in PEGDA without HA, and 4)
HCOAs encapsulated in Agar-HBMSCs encapsulated in PEGDA with HA was evaluated
using the Von-Kossa and Alcian Blue Stain kit (IHC world, Woodstock, MD, USA).
Briefly the samples from each group were first fixed in 10% formalin. They were then
embedded in molds using OCT. Sections were cut using cryostat (25 micron thickness) and
were stained using the manufacturer’s protocols. In short, sectioned samples were first
washed with PBS three times to remove the OCT. Then they were treated with silver nitrate
solution and exposed to UV light for 60 minutes. Next, they were stained with Alcian Blue
Stain, washed with distilled water and observed under a microscope to visualize both the
calcium and cartilage matrix deposition at the same time on the same tissue section.
5.3.8.1 Energy-Dispersive X-ray Spectroscopy
To quantify the composition of elements found within the transition zone of two
distinct engineered tissue matrices treated with HA, energy-dispersive x-ray spectroscopy
(EDS) was performed (JEOL 6330F Field Emission Scanning Electron Microscopy (FEG-
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SEM), (JEOL Ltd, Akishima-Shi, Tokyo). Specifically in an effort to obtain unambiguous
spectra, because the transition zone between engineered cartilage and bone possessed a
relatively large spatial region for assessment. For continuity in the text, the EDS results are
presented directly in the “Discussion” section since they were obtained to primarily
corroborate our histological findings,
5.3.9 Quantitative Real Time-Polymerase Chain Reaction q(RT-PCR)
To assess the gene expression of the stem cell-generated de novo cartilage tissue,
quantitative real time-polymerase chain reaction (qRT-PCR) analysis was conducted, both
at the interface and at the spatial location 4 cm from the interface, well within the stem-cell
derived engineered tissues. First, engineered cartilage derived from HBMSC’s after 28
days of culture was extracted from each group (1. HCs encapsulated in Agar-HBMSCs
encapsulated in PEGDA without HA 2. HCs encapsulated in Agar-HBMSCs encapsulated
in PEGDA with HA, 3. HCOAs encapsulated in Agar-HBMSCs encapsulated in PEGDA
without HA, and 4. HCOAs encapsulated in Agar-HBMSCs encapsulated in PEGDA with
HA.).
Each sample was subsequently cut into 2 parts. One part comprised of the transition region
of 1 cm and the remaining part of the spatial region of the engineered cartilage from
HBMSCs. Three samples from each group were cut in the similar fashion and, crushed and
pooled together for analysis. This was repeated for another 2 samples from each group that
generated a total number of pooled samples as n=3 for each of the interfacial and distal
cartilage locations for q(RT-PCR) assessment. Total mRNA was extracted from each group
three times using the SV total RNA isolation kit (Promega, Madison, WI). Subsequently,

95

the RNA isolation procedure was followed as described by the manufacturer (Promega).
Next, 5µg of mRNA was used for the reverse transcriptase reaction as previously reported
[25, 26]. GoScript Reverse Transcription kit (Promega) was used for converting the mRNA
for the four groups into cDNA using an oligo(dT) primer, according to the manufacturer’s
instructions.
The qRT-PCR was performed using the GoTaq_qPCR Master Mix (Promega). The
forward and reverse primers and SYBR green I dye reagent along with the cDNA, which
was obtained during reverse transcription were mixed in PCR tubes. The primers (Table 1)
were designed using the Basic Local Alignment Search Tool (BLAST) program, National
Center for Biotechnology Information (NCBI) to amplify the target sequences. Step-One
Real-Time PCR System (Life Technologies) was used to detect the signals when the
mixture was followed by thermal cycling conditions as per manufacturer’s instructions
(Promega). Finally, the expression of the following markers: GAPDH, Aggrecan, SOX9,
Collagen II, MMP13, Runx2, Collagen X, Collagen I, Osteocalcin were measured for the
different groups. The choice of these markers was made mainly to access the quality of
formed de novo cartilage. Aggrecan, Sox9 and Collagen II were selected as they were
healthy cartilage specific markers [27, 28]. High expression of MMP13, Runx2, Collagen
I were the indication of the deep zone calcified cartilage or hypertrophic cartilage [29, 30].
High expression of Collagen I and osteocalcin indicated the formation of oteoarthritic
cartilage [31]. Finally, to interpret the results, the change in cycle threshold (Cт) values
were averaged and normalized with GAPDH using the ΔΔCт method [32]. Fold changes
were calculated as 2- ΔCт, and the gene expression ratio of each of the four groups was
plotted.

96

5.3.10 Statistics
Statistical analysis was performed for the results obtained from cell viability, shear
testing and q(Rt-PCR). The results obtained were reported as means ± standard deviation.
Commercially available software (SPSS, IBM, version 20, Armonk, NY, USA) was used
to perform the statistics. To compare means and to determine statistically significant
differences (p < 0.05) between groups respectively for shear testing a one way ANOVA
and post hoc Tukey test was used. In cases where only two groups were compared, t-test
for independent groups was utilized.

Table 5.1: Quantitative RT-Polymerase Chain Reaction Primer Sequences
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5.4 Results
5.4.1 Cell Viability
The viability of the cells in the engineered scaffolds was observed over a period of
28 days at 4 time points (Day 1, Day 7, Day 14 and Day 28). We found that the HCs (Fig.
5.1 (a)) and HCOAs (Fig. 5.1 (b)) were both viable more than 85% in the Agar gel at 28
days of growth (Table 5.2).

Figure 5.1 (a): Live Dead assay over a period of 28 days for HCs encapsulated in agar scaffold.
The images clearly showed that cells remained viable over this time frame with a much larger
density of live (green dots) versus dead (red dots) cells
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Figure 5.1 (b): Live Dead assay over a period of 28 days for HCOAs encapsulated in agar
scaffold. The images clearly showed that cells remained viable over this time frame with a much
larger density of live (green dots) versus dead (red dots) cells
Table 5.2 Quantitative assessment of percentage cell viability in samples subjected to the livedead assay

5.4.2 Mechanical Testing
The integration of tissue engineered cartilage derived from HBMSC’s (with and
without HA nanoparticles) with healthy and diseased cartilage matrix mimics was assessed.
We found a statistically significant (p<0.05) difference in the shear strength between HCs
encapsulated in Agar - HBMSCs encapsulated in PEGDA without HA

and HCs

encapsulated in Agar - HBMSCs encapsulated in PEGDA with HA after both 7 days and
28 days of tissue culture (Fig. 2). Furthermore the integration strength of HCs encapsulated
in Agar - HBMSCs encapsulated in PEGDA without HA was significantly higher (p<0.05)
than the integration strength of HCs encapsulated in Agar - HBMSCs encapsulated in
PEGDA with HA group after 28 days of tissue culture. It was in the order of 6.87 ± 0.74

99

KPa for HCs encapsulated in Agar - HBMSCs encapsulated in PEGDA without HA.
Meanwhile the corresponding group with HA demonstrated shear strength of 5.55 ± 0.36
KPa. (Fig. 5.2)

Figure 5.2: Interfacial shear test results of tissue engineered cartilage joined with healthy cartilage
mimics with and without the presence of HA. The “*” indicates that the difference between the
groups was statistically significant (p < 0.05). Enhanced integration of tissue engineered cartilage
with healthy cartilage at day 28 compared to day 1 was found in both groups. However, there was
a significant increase (p < 0.05) in interfacial shear strength at day 28 when HA was not present.
This finding demonstrated that the presence of HA did not promote integration in healthy
cartilage environments

When comparing the shear strength of engineered cartilage with diseased cartilage
mimics with and without the inclusion of HA nanoparticles, we found that there was a
statistically significant difference in shear strength at all-time points (Day 7, Day 14 and
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Day 28) between HCOAs encapsulated in Agar - HBMSCs encapsulated in PEGDA
without HA and HCOAs encapsulated in Agar - HBMSCs encapsulated in PEGDA with
HA. We also found that the HCOAs-based samples which included HA nanoparticles
exhibited statistically significant (p<0.05) higher shear strength when compared with the
group without the HA nanoparticles. The value of shear strength after 28 days of tissue
culture was found to be 5.39 ± 0.25 KPa while for the corresponding group without HA, it
was in the order of 4.16 ± 0.8 KPa (Fig. 5.3).

Figure 5.3: Interfacial shear test results of tissue engineered cartilage joined with osteoarthritic
cartilage mimics with and without presence of HA. The “*” indicates that the difference between
the groups was statistically significant (p < 0.05). Enhanced integration of tissue engineered
cartilage with osteoarthritic cartilage at day 28 compared to day 1 was found in both groups.
However, there was a substantial increase in interfacial shear strength at day 28 when HA was
present. This finding demonstrated that the presence of HA significantly (p < 0.05) promoted
integration in osteoarthritic cartilage environments.
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5.4.3 Histology
Histological sections revealed that HCs encapsulated in Agar-HBMSCs encapsulated in
PEGDA with HA did not form a transition zone, but instead presented with a physical
spacing or gap between the two engineered constructs (Fig. 5.4). By transition zone, we
refer to a defined spatial region located between the tissue engineered two-layer constructs
(e.g. between HBMSCs engineered cartilage and HCs / HCOAs engineered cartilage), that
is made up of heterogeneous components derived from the two layers and is relatively
much larger than the size of the actual interface. However regardless of whether or not HA
was present, a narrowing of the gap was observed to have occurred in the constructs at 28
days in comparison to samples evaluated after 1 day of tissue culture (Fig. 5.4).
After 28 days of tissue culture, in HCOAs encapsulated in Agar-HBMSCs
encapsulated in PEGDA with HA, a thin transition zone was formed between HBMSCderived engineered cartilage and HCOA-derived cartilage; on the other hand, when HA
was not utilized, only a narrowing of the gap between the two layers was observed as was
previously seen in the HC groups (Fig 5.5).
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Figure 5.4: Von Kossa - Alcian Blue histology of tissue engineered cartilage derived from
HBMSCs integrated to HC-secreted cartilage matrix with and without HA incorporation. At Day
1, a clear gap was apparent between the engineered cartilage and healthy cartilage regions for
both groups. Progressive narrowing and filling of tissue subsequently occurred.
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Figure 5.5: Von Kossa - Alcian Blue histology of tissue engineered cartilage derived from
HBMSCs integrated to HCOA-secreted cartilage matrix with and without HA incorporation. At
Day 1, a clear gap was apparent between the engineered cartilage and diseased cartilage regions
for both groups. Progressive filling of the transition zone with calcium phosphate deposits
(indicated by dotted yellow lines) in the group with HA was found to occur.

5.5.4 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
After 28 days of culture in chondrogenic media, it was observed that HBMSCs
derived tissue engineered cartilage within HCs encapsulated in Agar-HBMSCs
encapsulated in PEGDA without HA exhibited relatively high expression of Aggrecan,
SOX9 and Collagen II genes in both the proximal and distal regions (relative to the
interface with HCs-derived engineered cartilage). In addition, there was a higher gene
expression of MMP13, Runx2 and collagen X at proximal to the interface but not at the
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distal region in HBMSCs derived tissue engineered cartilage within HCs encapsulated in
Agar-HBMSCs encapsulated in PEGDA with HA (Fig. 5.6).

Figure 5.6: q(RT-PCR) of HBMSCs derived engineered cartilage integrated to HC-secreted
cartilage matrix at a region of 1 cm (proximal) and 4cm (distal) from the interface within the
HBMSC portion. In samples with and without HA, the results indicated a high expression of
Aggrecan, SOX9 and Collagen II genes at both the proximal and distal positions, indicating the
formation of healthy cartilage. In addition, in the samples with HA, high gene expression of
MMP13, Runx2 and collagen X at the proximal location was found, indicating the presence of a
calcified cartilage matrix at the interface.

Similarly, for HBMSCs derived cartilage within HCOAs encapsulated in AgarHBMSCs encapsulated in PEGDA without HA, it was found that there was a relatively
higher gene expression of Sox9, Collagen II, MMP13, Runx2, Collagen X, osteocalcein at
the interface as well as to the regions deep within the HBMSCs-secreted engineered matrix.
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Gene expression of Type I collagen was nonetheless high at both the interface and deep in
the HBMSCs derived engineered cartilage within HCOAs encapsulated in Agar-HBMSCs
encapsulated in PEGDA without HA sample. However, when HA was incorporated, there
was no gene expression of Type 1 collagen at the distal region and minimal expression of
this gene at the interface (Fig. 5.7).

Figure 5.7: q(RT-PCR) of HBMSCs derived engineered cartilage integrated to HCOA-secreted
cartilage matrix at a region of 1 cm (proximal) and 4cm (distal) from the interface within the
HBMSC portion. In samples without HA, the results indicated a high expression of Type 1
collagen at both the proximal and distal positions, indicating a loss of the articular cartilage
phenotype in the presence of osteoarthritic environments. On the other hand, Type 1 collagen
expression was found to be minimal in the samples with HA; in addition high gene expression of
MMP13, Runx2 and collagen X at the proximal interface location was observed, indicating the
presence of a calcified cartilage matrix at the interface. Meanwhile these genes were minimally
expressed at locations deep within the BMSC-derived engineered tissues and yet, strong
expression of Aggrecan, SOX9, and Collagen II was maintained, indicative of a robust articular
cartilage phenotype, when HA was incorporated.
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5.5 Discussion
Over the past decade, extensive research has been conducted in the area of tissue
engineered cartilage integration with native tissues [33-35]. However most if not all of the
previous studies focused on integration between engineered cartilage to bone [35, 36]; yet
of equal importance is the need for effective integration of the engineered cartilage with
surrounding native articular cartilage, especially in the case of focal chondral defects. We
thus sought to build on our previous work [19] on enhanced integration between cartilage
and bone matrix using HA in a similar manner in this study, except to examine the utility
of HA nanoparticles to promote the anchorage and integration of engineered cartilage to
healthy as well as osteoarthritic cartilage extracellular matrix.
We found a significantly higher shear strength (p<0.05; Fig. 5.2) after 28 days of
tissue culture in HCs encapsulated in Agar-HBMSCs encapsulated in PEGDA without HA
constructs in comparison to equivalent constructs with HA. From this observation, we
interpret that matrix produced by HCs, that incorporates HA does not promote chondralchondral integration but rather, that the HA particles aggregate as non-heterogonous
components along the interface of the two materials which ultimately results in reduction
of shear strength. In contrast however, after 28 days of culture, we found a significantly
higher shear strength (p<0.05; Fig. 5.3) in HCOAs encapsulated in Agar-HBMSCs
encapsulated in PEGDA with HA in comparison to its without HA counterpart.
Interestingly thus, an opposing effect was observed (compared to HC-derived matrix) in
the presence of osteoarthritis wherein the HA did support significant improvement in
interfacial strength, and hence more effective integration between the two tissue matrices.
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These findings under a diseased state were consistent with our earlier work on HA-interface
promotion at the engineered cartilage to engineered bone interface [19].
Following Von Kossa staining of the samples with and without HA in healthy and
osteoarthritic-chondrogenic environments, a narrowing of the gap for both HCs
encapsulated in Agar-HBMSCs encapsulated in PEGDA with and without HA was
observed after 28 days of tissue culture (Fig. 5.4). In both cases, an intermediate transition
zone between the HBMSC and chondrocyte-derived engineered cartilage matrices was
absent. This corroborated with the decrease in the interfacial strength of the tissue
engineered cartilage with the healthy cartilage when HA was present and in-line with the
observation that a sharper or more abrupt transition between the two matrices, i.e., a smaller
spatial transition zone is indicative of less effective integration [21].
On the other hand, after 28 days of culture in HCOAs encapsulated in AgarHBMSCs encapsulated in PEGDA with HA, we observed the formation of a thin transition
zone (Fig. 5.5). This transition zone was largely occupied by calcium phosphate deposits.
Notably similar presence of calcium phosphate but in larger quantities was observed in our
previous studies, examining tissue engineered cartilage with HA integrated with an
osteoblast-derived bone matrix [19]. Subsequent EDS analysis in the transition zone
between these tissues confirmed a quantity of elemental Calcium in the order of  6.41 %
(Fig. 5.8). This finding provided conclusive evidence that the transition zone that was
created was due to the presence of calcium phosphate deposits, which was likely
attributable to the presence of the HA nanoparticles that had settled solely along the
interface location.
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Figure 5.8: Elementary composition of the transition zone using Energy-Dispersive X-ray
Spectroscopy. A large transition region between engineered cartilage and engineered bone
treated with HA was analyzed after 28 days of culture. Elemental Calcium in the order of  6.41
% was found to be present in the transition zone.

Further, we observed that in samples without HA, the BMSC-portion of HCs
encapsulated in Agar-HBMSCs encapsulated in PEGDA exhibited a healthy cartilage
phenotype after 28 days of culture (Fig. 5.6). However, when HA was incorporated there
was a high expression of the genes, MMP13, Runx2 and Type 2 Collagen at the proximal
region. This confirmed the presence of a calcified articular cartilage matrix at the interface,
even though a larger spatial transition zone was absent. We note that this calcified matrix
is likely to be similar in biochemical composition to the calcified matrix found in the deep
zone of normal healthy articular cartilage [37]. Corresponding HBMSC regions integrated
with HCOA-derived cartilage matrix without HA, revealed a high expression of Type 1
Collagen in both proximal and distal regions to the interface, i.e., indicative of a loss of
articular cartilage phenotype in osteoarthritic environments. On the other hand, Type 1
Collagen expression was found to be minimal at proximal locations to the interface when
HA was incorporated (Fig. 5.7). Finally, distal locations deep within the HBMSC-derived
engineered tissue did not express MMP13, runx2 and Type X Collagen; instead, a high
level of expression of the healthy articular cartilage genes, Sox9, aggrecan and Type II
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Collagen was observed demonstrating that the HBMSC-derived engineered tissues
preserved a healthy cartilage phenotype despite its integration with extracellular matrix
secreted by HCOAs. As previously stated, Type 1 collagen is a phenotypic indicator of
the arthritic-state in articular cartilage [38]. We speculate that the presence of HA at the
interface and the subsequent creation of a calcium phosphate-rich transition zone served to
reduce the spread of osteoarthritic conditions to the de novo cartilage formed by the
HBMSCs. Ironically however, the osteoarthritic state of adjacent cartilage matrix is a
necessary precursor to initiate calcium phosphate generation at the interface location
because calcium phosphate was found to be absent when the adjacent environment
comprised of engineered cartilage derived from healthy chondrocytes. From a clinical
perspective, we note that following cartilage injury, osteoarthritis rapidly develops [39-41]
and is usually a co-morbidity when small to medium size cartilage defects [42] are present.
Even though our results appear promising and our HA-based protocol could
potentially be transferred directly to clinical photopolymerizable tissue engineered
cartilage strategies currently being investigated [16, 43], we note that all our findings were
obtained from in vitro experiments. Specifically, we observed an increase in integration
shear strength of engineered cartilage with the osteoarthritic cartilage when HA particles
were incorporated. However, the critical strength that would be needed clinically for
effective engineered cartilage retention in order to permit an adequate amount of time for
subsequent tissue regeneration within the defect space has not been identified to date.
In summary, we were able to demonstrate substantial improvement in the
integration of engineered cartilage to an underlying layer of osteoarthritic cartilage matrix
in the presence of HA nanoparticles. The interfacial strength and histology results
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suggested that the utility of HA particles is only beneficial to the chondral-chondral
integration when the chondrocyte-derived cartilage matrix is osteoarthritic. In such as state,
a calcified cartilage matrix manifests itself between HBMSC and HCOA derived
engineered cartilage tissues in the form of a larger, spatial transition zone region, thereby
forming a stronger and a more stable interface. The calcium-phosphate deposits formed via
incorporation of HA in the photopolymerizable gel also served to act as a physical barrier
that reduced or at least delayed the onset of osteoarthritis progression from the surrounding
environment to the HBMSC-derived de novo cartilage matrix.
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Chapter 6
Conclusions and Future work

6.1 Conclusions, limitations and future work
This study presented an overall approach to integration of tissue engineered
cartilage with bone, healthy and diseased cartilage matrices in an in-vitro environment. We
anticipate this protocol can be utilized for treatment of small to modest sized osteochondral
defects so as to prevent or at minimum, delay the onset of Osteoarthritis. The novelty of
this project was the use of HA nanoparticulate usage in HBMSC-seeded,
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photopolymerizable injectable hydrogels, to promote biological integration of engineered
cartilage to adjacent bone and cartilage matrices.
HA is a bioactive form of calcium phosphate Ca10(PO4)6(OH)2, has a Ca/P molar
ratio of 1.67 [2], and is considered osteoinductive [1]. For example, HA coatings in
implants have shown to promote bone in growth [3, 4, 5]. With a similar approach, here,
we proposed the use of HA nanoparticles for enhancing the anchorage and hence retention
of tissue engineered cartilage with surrounding native tissues (subchondral bone and
articular cartilage). For the studies conducted, in theory, we could have used any form of
calcium phosphate in nanoparticulate form with a molar ratio of Ca/P as 1.67. We selected
HA because it is the most predominant material in bone [6].
In this dissertation: Chapter 1 explained the area of tissue engineered cartilage and
the need to augment retention and integration properties of engineered cartilage within a
osteochondral or chondral defect space. Chapter 2 provided a critical review of previous
research that was done in this field and helped us to determine and frame our objectives
which were to: (i) promote the integration between engineered cartilage to subchondral
bone using HA nanoparticles in an optimized photopolymerizable hydrogel environment.
(ii) To enhance the integration between tissue engineered cartilage and surrounding native
cartilage, again with HA nanoparticle incorporation in photopolymerizable hydrogel
environments. (iii) To identify the impact of osteoarthritic diseased states, in
photopolymerizable hydrogel environments in conjunction with HA particles.
In chapter 3, we presented a toxicity study of different cell sources to different
levels of UV exposure and photoinitiator concentrations. This chapter formed the
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foundation for subsequent protocols that were designed in conjunction with in vitro
engineered tissue model systems for evaluating integration of engineered cartilage to bone,
healthy cartilage and diseased cartilage. From this investigation, we were able to select the
ideal UV exposure time and establish cellular response to UV exposure for subsequent
PEGDA-based experiments. Chapter 4 focused on the utility of HA nanoparticles for
integration of engineered cartilage to bone matrix. We were able to show a significant
improvement in the interfacial strength between engineered cartilage and subchondral bone
matrix when HA was used, via the formation of a calcium phosphate-rich transition zone
between the two materials.
We then subsequently tested the incorporation of HA particles for improving the
integration strength of engineered cartilage with underlying healthy and diseased cartilage,
the focus of Chapter 5. Surprisingly, Osteoarthritic cartilage yielded more effective
integration with HBMSC-originating engineered cartilage, in comparison to healthy
cartilage matrix derived from chondrocytes. We interpret the similarities in gene
expression between bone and Osteoarthritic cartilage to have enhanced HA activity,
thereby resulting in the greater integration observed.
Even though our results appear promising, we were limited in our scope and restricted to
in-vitro environments. Our model while exhibiting enhanced integration properties would
need to be able to withstand in vivo physiological loading conditions. Tissue remodeling
and growth would likely be very different from the observations of this study, which
therefore needs to be evaluated in our future work. In our laboratories, in conjunction with
our collaborators at Mississippi State University, we have already undertaken the first steps
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in this direction by utilizing the rabbit model. The specific protocol follows a similar
paradigm to the studies reported by Ramaswamy et al [7], and is likely to also at some
point involve noninvasive longitudinal assessment of engineered cartilage tissue
integration and repair using magnetic resonance imaging. At the time of submission of this
dissertation, surgically created chondral defects in osteoarthritic rabbit knees were treated
following a similar protocol developed from the current work on HBMSC-PEGDA-HA
constructs. Over the next calendar year, following animal sacrifice and knee explant, we
anticipate that a greater understanding and identification of in vivo integration processes
will be uncovered. Pending completion of the in vivo phase with a successful outcome, we
anticipate that our HA-based protocol can be directly assimilated into existing clinical
studies that are utilizing injectable hydrogel approaches for cartilage repair and
regeneration [8, 9] .
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